预约演示
更新于：2025-12-04
Azithromycin
阿奇霉素
更新于：2025-12-04
概要
基本信息
简介阿奇霉素是一种小分子药物，作用于细菌核糖体的50S亚基，通过抑制蛋白质合成来杀死细菌。它是一种广谱抗生素，可用于治疗多种细菌感染，包括肺炎、中耳炎、喉炎、皮肤感染和生殖系统感染等。阿奇霉素在治疗呼吸道感染方面特别有效，可以缩短治疗时间和减少复发率。它也被用于治疗梅毒和麻疹等疾病。这种药物于1991年首次批准上市，原研公司为辉瑞公司，现已成为临床使用最广泛的抗生素之一。 |
药物类型 小分子化药 |
别名 Azithromycin (INN)、Azithromycin Dihydrate、Azithromycin Hydrate + [30] |
作用方式 抑制剂 |
作用机制 50S subunit抑制剂(50S核糖体亚基抑制剂) |
非在研适应症 |
原研机构 |
最高研发阶段批准上市 |
首次获批日期 美国 (1991-11-01), |
最高研发阶段(中国)批准上市 |
特殊审评孤儿药 (美国)、优先审评 (中国)、孤儿药 (日本) |
登录后查看时间轴
结构/序列
分子式C38H72N2O12 |
InChIKeyMQTOSJVFKKJCRP-BICOPXKESA-N |
CAS号83905-01-5 |
关联
929
项与 阿奇霉素 相关的临床试验NCT05763693
Vitality in Infants Via Azithromycin for Neonates Trial
Nearly half of child deaths occur during the neonatal period, and 80% of those occur in babies with low birthweight. Although tremendous progress has been made towards reducing under-five mortality globally, declines in neonatal mortality lag behind those observed in older children. Low birthweight babies are at increased risk of poor outcomes compared to those who are term-appropriate for gestational age, including mortality, stunting, and growth failure. Recent evidence has demonstrated that the incidence of wasting and linear growth failure is highest between birth and 3 months of age, substantially earlier than previously thought. Interventions are urgently needed to improve outcomes in low birthweight babies; however, these interventions must not interfere with breastfeeding and thus some well-established interventions used to treat or prevent malnutrition in older children cannot be considered. The investigators recently demonstrated that biannual mass azithromycin distribution reduces all-cause childhood mortality by approximately 25% in infants aged 1-5 months, with stronger effects seen in underweight infants. This study did not include neonates due to the risk of infantile hypertrophic pyloric stenosis (IHPS) that has been hypothesized to be associated with macrolide use during early infancy. However, our study team documented only a single case of IHPS among 21,833 neonates enrolled in a trial of azithromycin versus placebo administered to neonates aged 8-27 days for prevention of infant mortality, documenting no major risk of IHPS associated with azithromycin. Here, the investigators propose an individually randomized trial where participants will receive a single oral dose of azithromycin (administered either during the neontal period or 21 days after enrollment), two does of oral azithromycin spaced 21 days apart, or two doses of placebo to evalute if azithromycin improves nutritional outcome and reduces infectious burden among neonates aged 1-27 days who are either low birthweight (<2500 g at birth) or underweight (weight-for-age Z-score < -2 at enrollment). The primary outcome will be weight-for-age Z-score at 6 months of age compared between arms. The investigators anticipate that the results of this study will provide definitive evidence on azithromycin as an early intervention for low birthweight/underweight neonates, who are at the highest risk of adverse outcomes.
开始日期2026-04-01 |
ACTRN12624000960550
ASAPP: Efficacy of Azithromycin for Short cervix and Amniotic fluid sludge for the Prevention of Preterm birth, a pilot randomised controlled trial
开始日期2025-11-20 |
申办/合作机构 |
CTR20252850
ZHCX002序贯给药在成人社区获得性肺炎患者中的药代动力学、安全性和疗效探索的I期临床研究
主要目的：考察注射用阿奇霉素和阿奇霉素干混悬剂序贯给药在成人社区获得性肺炎患者体内的药代动力学特征。
次要目的：
1.评价注射用阿奇霉素治疗成人社区获得性肺炎患者的安全性。
2. 评价注射用阿奇霉素治疗成人社区获得性肺炎患者的有效性。
3. 探索成人社区获得性肺炎患者PK/PD和PK/安全性的关系。
开始日期2025-11-03 |
申办/合作机构  九华华源药业股份有限公司 [+1] |
100 项与 阿奇霉素 相关的临床结果
登录后查看更多信息
100 项与 阿奇霉素 相关的转化医学
登录后查看更多信息
100 项与 阿奇霉素 相关的专利（医药）
登录后查看更多信息
17,203
项与 阿奇霉素 相关的文献（医药）2026-02-01·IMMUNOLOGY LETTERS
In vitro analysis of azithromycin’s effect on J774 murine macrophages challenged with Aspergillus fumigatus
Article
作者: Fortwendel, Jarrod R ; Antwi, Ivy ; Cory, Theodore J
BACKGROUND:
Patients with chronic lung diseases often suffer from pulmonary aspergillosis, caused by Aspergillus fumigatus (AF). Alveolar macrophages play a key role in the initial immune response to AF. Azithromycin (AZM), commonly known for its immunomodulatory properties in reducing exacerbations and improving lung function, has mixed effects on the development of aspergillosis. While some studies suggest AZM aids AF-colonized patients, others indicate increased rates of AF colonization.
OBJECTIVE:
Given AZM's positive impact on host response to other pathogens, we hypothesized that it would improve immune responses to AF by modulating macrophage function. We investigated the in vitro effect of AZM on J774 murine macrophage response to Aspergillus fumigatus.
METHOD:
The murine macrophage cell line J774 was polarized into distinct phenotypes: (1) classical M1 macrophages, generated using interferon-gamma (IFN-γ) and lipopolysaccharide (LPS); (2) azithromycin-treated M1 macrophages (hereafter referred to as M1A macrophages), generated by treating M1 cells with azithromycin in addition to IFN-γ and LPS; and (3) alternatively activated M2 macrophages, generated using interleukin-4 (IL-4), interleukin-13 (IL-13), and LPS. These polarized macrophages were then analyzed for cytokine production, fungal killing capacity, and reactive oxygen species (ROS) generation.
RESULTS:
We observed a shift in macrophage phenotype toward an anti-inflammatory-like profile in the AZM-treated group, characterized by an increased fungal killing compared to both M1- and M2-polarized groups. This was accompanied by a reduction in interleukin-6 (IL-6) cytokine production, an increase in arginase activity, without any significant change in ROS generation. Further assays confirmed that the observed increase in fungal clearance was attributable to AZM's impact on macrophages rather than any direct antifungal activity against Aspergillus fumigatus.
CONCLUSION:
These findings suggest AZM enhances macrophage function, boosting anti-inflammatory responses and improving fungal clearance.
2026-01-01·Indian Journal of Medical Microbiology
Prevalence of Chlamydia trachomatis, Ureaplasma spp., Mycoplasma hominis and Mycoplasma genitalium in patients with sterile pyuria
Article
作者: Soneja, Manish ; Vikram, Naval ; Dhawan, Benu ; Biswal, Debasish ; Wig, Naveet ; Rawre, Jyoti ; Aggarwal, Anivita ; Vishnubhatla, Sreenivas
INTRODUCTION:
Sterile pyuria poses a diagnostic challenge due to varied aetiologies. Atypical pathogens including Chlamydia trachomatis and genital mycoplasmas are considered etiological agents but are under-reported, especially in resource-limited settings. This study determined the prevalence of these atypical pathogens in sterile pyuria patients.
MATERIALS AND METHODS:
This 4-year prospective observational study screened 640 adults admitted to Medicine wards of a tertiary care hospital for sterile pyuria, defined as urine microscopy showing >10 WBCs/HPF with no bacterial growth on culture. All sterile pyuria patients were evaluated for Chlamydia trachomatis (CT), Ureaplasma spp., Mycoplasma hominis (MH) and Mycoplasma genitalium (MG) from first void urine samples. Mycoplasma hominis and Ureaplasma spp. were detected by culture and PCR assay. Chlamydia trachomatis was detected by PCR assay. Mycoplasma genitalium was detected by Real-time PCR assay. Additional assessments for other potential causes were carried out. Patients were treated with doxycycline or azithromycin and followed for outcomes. Risk factors for infection with these atypical agents were explored.
RESULTS:
Of 640 patients screened, 100 (15.6 %) had sterile pyuria. Atypical pathogens were detected in 40 %. CT, Ureaplasma spp., and MH were detected in 19 %, 15 % and 5 % respectively. One patient tested positive for MG. Multivariate logistic regression identified multiple sexual partners (adjusted OR 12.01, 95 % CI 2.07-69.40, p = 0.005) and past pelvic surgery (adjusted OR 5.64, 95 % CI 1.43-22.24, p = 0.013) as risk factors. Twenty-five (62.5 %) of 40 patients achieved complete clinical and microbiological cure with treatment. Laboratory records revealed genitourinary tuberculosis in 2 patients.
CONCLUSION:
This study identified 40 % prevalence of atypical pathogens in sterile pyuria patients. Unlike previous assumptions, genitourinary tuberculosis was not a common cause in our population. Our findings emphasize the necessity for comprehensive screening for CT, Ureaplasma spp., MH, and MG in sterile pyuria patients.
2026-01-01·INTERNATIONAL JOURNAL OF PHARMACEUTICS
Corrigendum to “Innovative bilayered buccal films: A paediatric-friendly dosage form for transmucosal azithromycin delivery”. [Int. J. Pharm. 684 (2025) 126164]
作者: Bigucci, Federica ; Imbriano, Anna ; Bertoni, Serena ; Fratini, Costanza ; Hasa, Dritan ; Pagano, Cinzia ; D'Abbrunzo, Ilenia ; Parolin, Carola ; Vitali, Beatrice ; Abruzzo, Angela ; Bondi, Giulia ; Sabbatini, Beatrice
589
项与 阿奇霉素 相关的新闻（医药）2025-12-03
Journal of Antimicrobial Chemotherapy Volume 80, Issue 7抗菌化疗杂志 80卷 7期
https://academic.oup.com/jac/issue
REVIEWS（综述）
1
The role of antimicrobial prophylaxis in brachytherapy for prostate, breast and gynaecological cancer: a narrative review
抗生素预防用药在前列腺、乳腺及妇科癌症近距离治疗中的作用：叙述性综述
Konstantinos Alexakis and others
Journal of Antimicrobial Chemotherapy, Volume 80, Issue 7, July 2025, Pages 1753–1771,
2
To be or not to be: the non-antimicrobial properties of common antimicrobials
生存还是毁灭：常见抗菌药物的非抗菌特性
Shivakumar Narayanan and others
Journal of Antimicrobial Chemotherapy, Volume 80, Issue 7, July 2025, Pages 1772–1783,
SYSTEMATIC REVIEWS（系统综述）
3
Antibiotic-induced Bartter-like syndrome: a systematic review
抗生素诱发的巴特综合征样表现：系统综述
Megha Priyadarshi and others
Journal of Antimicrobial Chemotherapy, Volume 80, Issue 7, July 2025, Pages 1784–1791,
4
Liposomal amphotericin B prophylaxis in paediatrics: a systematic review
两性霉素B脂质体预防性用药在儿科中的应用：系统综述
Emma V Thorley and others
Journal of Antimicrobial Chemotherapy, Volume 80, Issue 7, July 2025, Pages 1792–1802,
ORIGINAL RESEARCH（论著）
5
Antibiotic use attributable to RSV infections during infancy—an international prospective birth cohort study
婴儿期呼吸道合胞病毒感染所致抗生素使用情况——一项国际前瞻性出生队列研究
Sarah F Hak and others
Journal of Antimicrobial Chemotherapy, Volume 80, Issue 7, July 2025, Pages 1803–1812,
6
Plasmodium falciparum isolates: ex vivo drug response
恶性疟原虫分离株：体外药物反应
Edem Adika and others
Journal of Antimicrobial Chemotherapy, Volume 80, Issue 7, July 2025, Pages 1813–1822,
7
Impact of hypoalbuminemia on patients receiving ertapenem combination therapy for methicillin-susceptible Staphylococcus aureus bacteraemia
低白蛋白血症对接受厄他培南联合疗法治疗甲氧西林敏感金黄色葡萄球菌菌血症患者的影响
Sunish Shah and others
Journal of Antimicrobial Chemotherapy, Volume 80, Issue 7, July 2025, Pages 1823–1827,
8
Exploring community pharmacy professionals and general practitioners’ views on primary care communication and pathways to access antibiotics in England
探究英国社区药房专业人员和全科医生对初级保健沟通及获取抗生素途径的看法
Ming Xuan Lee and others
Journal of Antimicrobial Chemotherapy, Volume 80, Issue 7, July 2025, Pages 1828–1836,
9
Decline of antimicrobial resistance in Pseudomonas aeruginosa bacteraemia following the COVID-19 pandemic: a longitudinal observational study
新冠疫情后铜绿假单胞菌菌血症抗菌药物耐药性的下降：一项纵向观察研究
Yulia Butscheid and others
Journal of Antimicrobial Chemotherapy, Volume 80, Issue 7, July 2025, Pages 1837–1848,
10
Selected comorbidities and the probability of ART switch in PWH with undetectable HIV-RNA: a retrospective analysis in Italy
意大利HIV感染者（HIV-RNA不可检测）特定合并症与抗逆转录病毒药物转换概率：一项回顾性分析
Alessandro Cozzi-Lepri and others
Journal of Antimicrobial Chemotherapy, Volume 80, Issue 7, July 2025, Pages 1849–1859,
11
Model-based translation of the PKPD-relationship for linezolid and vancomycin on methicillin-resistant Staphylococcus aureus: from in vitro time–kill experiments to a mouse pneumonia model
基于模型转化利奈唑胺和万古霉素对甲氧西林耐药金黄色葡萄球菌的药代动力学-药效学关系：从体外时间杀菌实验到小鼠肺炎模型
Diego Vera-Yunca and others
Journal of Antimicrobial Chemotherapy, Volume 80, Issue 7, July 2025, Pages 1860–1868,
12
Inner-mitochondrial membrane protein PfMPV17 is linked to P. falciparum in vitro resistance to the indoloquinolizidine alkaloid alstonine
线粒体内膜蛋白PfMPV17与恶性疟原虫对吲哚醌啉生物碱阿尔斯通宁的体外耐药性相关
J R Macdonald and others
Journal of Antimicrobial Chemotherapy, Volume 80, Issue 7, July 2025, Pages 1869–1877,
13
Efficacy and tolerability of the combination of minocycline and metronidazole for macrolide-resistant Mycoplasma genitalium
米诺环素与甲硝唑联合治疗大环内酯类耐药生殖支原体感染的疗效和耐受性
Kay Htaik and others
Journal of Antimicrobial Chemotherapy, Volume 80, Issue 7, July 2025, Pages 1878–1884,
14
Early use of the novel antifungal rezafungin: a case series and literature review
新型抗真菌药物瑞扎芬净的早期使用：病例系列报道及文献综述
H C Davidson and others
Journal of Antimicrobial Chemotherapy, Volume 80, Issue 7, July 2025, Pages 1885–1892,
15
Optimal dosing of amoxicillin in obese and post-gastric bypass patients using a population pharmacokinetics-pharmacodynamics model approach
基于群体药代动力学-药效学模型方法确定阿莫西林在肥胖和胃旁路术后患者中的最佳剂量
Gisela Myrian de Lima Leite Dalla Rosa and others
Journal of Antimicrobial Chemotherapy, Volume 80, Issue 7, July 2025, Pages 1893–1901,
16
Decreasing antimicrobial resistance in representative UK livestock species was associated with reduced total sales of antimicrobials in the last decade
过去十年，英国代表性家畜物种抗菌药物耐药性下降与抗菌药物总销量减少相关
Aliya El Nagar and others
Journal of Antimicrobial Chemotherapy, Volume 80, Issue 7, July 2025, Pages 1902–1906,
17
An improved multiplex RT–quantitative PCR assay can reveal sex-specific activity of transmission-blocking drugs on ex vivo gametocytes from Plasmodium falciparum asymptomatic infections
一种改进的多重逆转录定量聚合酶链反应检测法可揭示性特异性抗疟疾传播阻断药物对恶性疟原虫无症状感染体外配子体活性的影响
Mariagrazia Ciardo and others
Journal of Antimicrobial Chemotherapy, Volume 80, Issue 7, July 2025, Pages 1907–1914,
18
Population pharmacokinetics and thrombocytopenia risk assessment of linezolid in liver transplant recipients
利奈唑胺在肝移植受者中的群体药代动力学及血小板减少症风险评估
Xiaoping Shi and others
Journal of Antimicrobial Chemotherapy, Volume 80, Issue 7, July 2025, Pages 1915–1925,
19
Rapid susceptibility testing on urine for antimicrobial stewardship in general practice
全科实践中的尿液快速药敏试验助力抗菌药物管理
Patrick D J Sturm and Tanja Schülin
Journal of Antimicrobial Chemotherapy, Volume 80, Issue 7, July 2025, Pages 1926–1932,
20
Efficacy of linezolid in monotherapy q12h versus q8h versus combined with daptomycin in the treatment of experimental endocarditis caused by methicillin-resistant and glycopeptide-intermediate Staphylococcus aureus strains
利奈唑胺单药治疗每12小时一次与每8小时一次，以及与达托霉素联合治疗甲氧西林耐药和糖肽中介金黄色葡萄球菌菌株所致实验性心内膜炎的疗效
María-Alexandra Cañas and others
Journal of Antimicrobial Chemotherapy, Volume 80, Issue 7, July 2025, Pages 1933–1941,
21
In vitro activity of NOSO-502, a novel-action antimicrobial, against clinical strains of Enterobacterales including MDR strains
新型作用机制抗菌药物NOSO-502对包括多重耐药菌株在内的肠杆菌科临床菌株的体外活性
Marie L G Attwood and others
Journal of Antimicrobial Chemotherapy, Volume 80, Issue 7, July 2025, Pages 1942–1946,
22
Antibacterial activity of propylene glycol against Staphylococcus aureus and Staphylococcus epidermidis in neutral and mild acidic conditions
中性及弱酸性条件下，丙二醇对金黄色葡萄球菌和表皮葡萄球菌的抗菌活性
Nadiia Mosiichuk and others
Journal of Antimicrobial Chemotherapy, Volume 80, Issue 7, July 2025, Pages 1947–1950,
23
Molecular characteristics of chromosome-mediated colistin resistance in foodborne Salmonella isolates in China
中国食源性沙门氏菌分离株染色体介导的多粘菌素耐药性的分子特征
Zeqiang Zhan and others
Journal of Antimicrobial Chemotherapy, Volume 80, Issue 7, July 2025, Pages 1951–1963,
24
High azole non-wild type rates and nosocomial microsatellite typing aggregation of Wickerhamomyces anomalus in China according to a 12-year multicenter surveillance study
根据一项为期12年的多中心监测研究，中国异常威克汉姆酵母属唑类非野生型率高且医院内微卫星分型聚集
Zhengyu Luo and others
Journal of Antimicrobial Chemotherapy, Volume 80, Issue 7, July 2025, Pages 1964–1971,
25
Repurposing antimalarials: pyrimethamine exhibits superior in vitro activity to metronidazole against Gardnerella while sparing Lactobacillus
抗疟药物再利用：乙胺嘧啶对加德纳菌的体外活性优于甲硝唑，且对乳酸杆菌无影响
Aliona S Rosca and others
Journal of Antimicrobial Chemotherapy, Volume 80, Issue 7, July 2025, Pages 1972–1979,
26
Clinical characteristics and risk factors of tigecycline-induced acute pancreatitis in kidney transplant recipients: a retrospective study
肾移植受者替加环素诱发急性胰腺炎的临床特征及危险因素：一项回顾性研究
Lijuan Feng and others
Journal of Antimicrobial Chemotherapy, Volume 80, Issue 7, July 2025, Pages 1980–1987,
27
Genomic characteristics of the multiresistant Acinetobacter baumannii global clone 1 reference strain A297/RUH875
多重耐药鲍曼不动杆菌全球克隆1型参考菌株A297/RUH875的基因组特征
Jonathan Koong and others
Journal of Antimicrobial Chemotherapy, Volume 80, Issue 7, July 2025, Pages 1988–1992,
28
Comparison of a modified broth microdilution Sensititre™ SLOMYCOI assay with the CLSI-recommended agar disk elution method for antimicrobial susceptibility testing of Mycobacterium haemophilum
改良肉汤微量稀释Sensititre™ SLOMYCOI检测法与CLSI推荐的琼脂稀释法对嗜血杆菌属抗菌药物敏感性检测的比较
Doris Hillemann and others
Journal of Antimicrobial Chemotherapy, Volume 80, Issue 7, July 2025, Pages 1993–1996,
29
Reversal of phenotypic resistance in multi-drug resistant carbapenemase-producing K. pneumoniae clinical isolates due to in vitro synergistic interactions between bacteriophages and antibiotics at clinically achievable concentrations
由于细菌噬菌体和抗生素在临床可达到浓度下的体外协同作用，多重耐药碳青霉烯酶产生肺炎克雷伯菌临床分离株的表型耐药性发生逆转
Paschalis Paranos and others
Journal of Antimicrobial Chemotherapy, Volume 80, Issue 7, July 2025, Pages 1997–2006,
30
Antibiotic resistance and population structure of Staphylococcus epidermidis from prosthetic joint infections in Sweden and France
瑞典和法国假体关节感染表皮葡萄球菌的抗生素耐药性和群体结构
Sofie M Edslev and others
Journal of Antimicrobial Chemotherapy, Volume 80, Issue 7, July 2025, Pages 2007–2015,
31
Lines on the line: evaluating the impact of antibiotic lock therapy versus catheter removal in the management of central vascular catheter infections
抗生素锁疗法与导管拔除术治疗中心血管导管感染的影响评估
Nischal Ranganath and others
Journal of Antimicrobial Chemotherapy, Volume 80, Issue 7, July 2025, Pages 2016–2024,
32
Real-time FT-IR typing of Klebsiella pneumoniae: a flexible and rapid approach for outbreak detection and infection control
肺炎克雷伯菌实时傅里叶变换红外分型：一种灵活快速的暴发检测和感染控制方法
Ana Beatriz Gonçalves and others
Journal of Antimicrobial Chemotherapy, Volume 80, Issue 7, July 2025, Pages 2025–2031,
33
Antibiotic stress affects the secretion and physicochemical features of extracellular vesicles produced by Helicobacter pylori
抗生素压力影响幽门螺杆菌产生的细胞外囊泡的分泌和物理化学特性
Paweł Krzyżek and others
Journal of Antimicrobial Chemotherapy, Volume 80, Issue 7, July 2025, Pages 2032–2043,
34
A novel azithromycin resistance mutation in Mycoplasma genitalium induced in vitro
生殖支原体体外诱导产生的新型阿奇霉素耐药突变
Teck-Phui Chua and others
Journal of Antimicrobial Chemotherapy, Volume 80, Issue 7, July 2025, Pages 2044–2050,
RESEARCH LETTERS（研究信函）
35
Posaconazole dosing of enteral formulations in infants and young children to achieve therapeutic concentrations
婴儿和幼儿肠内制剂泊沙康唑的给药剂量以达到治疗浓度
Jeffrey Harrington and others
Journal of Antimicrobial Chemotherapy, Volume 80, Issue 7, July 2025, Pages 2051–2053,
36
Antimony used as rescue therapy in a kidney transplant recipient unresponsive to liposomal amphotericin B for chronic visceral leishmaniasis
两性霉素B脂质体治疗慢性内脏利什曼病无效的肾移植受者中使用锑剂作为挽救疗法
Natacha Mrozek and others
Journal of Antimicrobial Chemotherapy, Volume 80, Issue 7, July 2025, Pages 2053–2056,
37
Is cefazolin an option for treatment of staphylococcal endogenous endophthalmitis?
头孢唑林是否可用于治疗葡萄球菌性内源性眼内炎？
Alexandra Morin and others
Journal of Antimicrobial Chemotherapy, Volume 80, Issue 7, July 2025, Pages 2057–2058,
LETTER TO THE EDITOR（致编辑的信）
38
Use of teicoplanin monotherapy for the treatment of enterococcal infective endocarditis: a retrospective and comparative study at a referral centre—a counterpoint
单用替考拉宁治疗肠球菌感染性心内膜炎：一家转诊中心的回顾性和比较研究——反驳观点
Miguel Villamarín and others
Journal of Antimicrobial Chemotherapy, Volume 80, Issue 7, July 2025, Pages 2059–2060,
Journal of Antimicrobial Chemotherapy Volume 80, Issue 8
抗菌化疗杂志 80卷 8期
https://academic.oup.com/jac/issue
Review(综述)
1
World Health Organisation’s Bacterial Pathogen Priority List (BPPL) 2017 and BPPL 2024 to combat global antimicrobial resistance crisis: ‘challenges and opportunities’
世界卫生组织2017年和2024年用以应对全球抗菌药物耐药性危机的细菌病原体优先名单（BPPL）：“挑战与机遇”
Vazhayil Hari Krishnaprasad and others
Journal of Antimicrobial Chemotherapy, Volume 80, Issue 8, August 2025, Pages 2061–2069
Original Research(论著)
2
Aztreonam/avibactam activity against Enterobacterales from European medical centres: summary of 5years of surveillance prior to approval for clinical use (2019–2023)
氨曲南/阿维巴坦对欧洲医疗中心肠杆菌科细菌的活性：临床批准前5年（2019-2023年）监测总结
Helio S Sader and others
Journal of Antimicrobial Chemotherapy, Volume 80, Issue 8, August 2025, Pages 2070–2079
3
High feasibility of salivary therapeutic drug monitoring in linezolid, but lower feasibility in tedizolid: a single-dose study in healthy subjects and a monocentric prospective exploratory study in patients who received linezolid
利奈唑胺唾液治疗药物监测可行性高，但替地唑胺可行性较低：一项健康受试者单剂量研究和一项接受利奈唑胺患者单中心前瞻性探索性研究
Hitoshi Kawasuji and others
Journal of Antimicrobial Chemotherapy, Volume 80, Issue 8, August 2025, Pages 2080–2091
4
Establishment and validation of downsized hollow-fibre infection model and pharmacokinetics/pharmacodynamics analysis of VAN on Enterococcus faecium
缩小版中空纤维感染模型的建立与验证及万古霉素对粪肠球菌的药代动力学/药效学分析
Yukitaka Hayashi and others
Journal of Antimicrobial Chemotherapy, Volume 80, Issue 8, August 2025, Pages 2092–2099
5
Four-month clofazimine regimen for susceptible pulmonary TB: a randomized clinical trial
为期4个月的氯法齐明方案治疗敏感型肺结核：一项随机临床试验
Nusrat Shafiq and others
Journal of Antimicrobial Chemotherapy, Volume 80, Issue 8, August 2025, Pages 2100–2108
6
An ex vivo model to determine transmembrane clearance of antimicrobials during continuous renal replacement therapy
用于确定连续性肾脏替代治疗期间抗菌药物跨膜清除率的体外模型
Cole McGrath and others
Journal of Antimicrobial Chemotherapy, Volume 80, Issue 8, August 2025, Pages 2109–2116
7
Optimization and improvement of the disc diffusion method for mucoid Pseudomonas aeruginosa
黏液型铜绿假单胞菌纸片扩散法的优化与改进
Aixin Wang and others
Journal of Antimicrobial Chemotherapy, Volume 80, Issue 8, August 2025, Pages 2117–2125
8
HIV-1 drug resistance among people living with HIV receiving dolutegravir-based anti-retroviral regimens in Uganda: a national laboratory-based survey using remnant viral load samples, 2022
乌干达接受基于多替拉韦抗逆转录病毒方案的HIV感染者中HIV-1耐药性情况：2022年一项基于国家实验室使用剩余病毒载量样本的调查
Christine Watera and others
Journal of Antimicrobial Chemotherapy, Volume 80, Issue 8, August 2025, Pages 2126–2134
9
Population pharmacokinetics of weight-based compared with fixed dosing of CAP256V2LS, a broadly neutralizing antibody for HIV prevention in women
与固定剂量相比，基于体重给药的CAP256V2LS（一种用于女性HIV预防的广谱中和抗体）群体药代动力学研究
Sharana Mahomed and others
Journal of Antimicrobial Chemotherapy, Volume 80, Issue 8, August 2025, Pages 2135–2144
10
Gut microbiota and weight gain in people with HIV on integrase inhibitors: a five-year longitudinal study
接受整合酶抑制剂治疗的HIV感染者肠道微生物群与体重增加情况：一项为期五年的纵向研究
Javier García-Abellán and others
Journal of Antimicrobial Chemotherapy, Volume 80, Issue 8, August 2025, Pages 2145–2157
11
Development of a ribavirin dosing regimen in transplant recipients with chronic hepatitis E virus infection: a population pharmacokinetic and -dynamic model
慢性戊型肝炎病毒感染移植受者利巴韦林给药方案的开发：一项群体药代动力学和药效学模型研究
Midas B Mulder and others
Journal of Antimicrobial Chemotherapy, Volume 80, Issue 8, August 2025, Pages 2158–2168
12
Effectiveness and predictors of treatment discontinuation of long-acting cabotegravir/rilpivirine in virologically suppressed people with HIV: real-life data from the Icona Cohort
长效卡博特韦/利匹韦林在病毒受抑制的HIV感染者中的治疗中断有效性和预测因素：来自Icona队列的现实数据
Roberta Gagliardini and others
Journal of Antimicrobial Chemotherapy, Volume 80, Issue 8, August 2025, Pages 2169–2178
13
Five-days-on-two-days-off (FOTO) versus daily bictegravir/emtricitabine/tenofovir alafenamide in virologically suppressed people with HIV: a pilot randomized clinical trial
病毒受抑制的HIV感染者中，5天用药2天停药（FOTO）方案与每日比克替拉韦/恩曲他滨/丙酚替诺福韦方案的对比：一项初步随机临床试验
Hsin-Yun Sun and others
Journal of Antimicrobial Chemotherapy, Volume 80, Issue 8, August 2025, Pages 2179–2186
14
Reliability of disc diffusion testing and molecular epidemiology of penicillin-susceptible Staphylococcus aureus bacteraemia
青霉素敏感金黄色葡萄球菌菌血症的纸片扩散试验可靠性和分子流行病学研究
Pernilla Kihlberg and others
Journal of Antimicrobial Chemotherapy, Volume 80, Issue 8, August 2025, Pages 2187–2193
15
Outcomes of ceftriaxone 2g versus 1g daily in hospitalized patients with pneumonia: a nationwide retrospective cohort study
住院肺炎患者每日头孢曲松2克与1克疗效对比：一项全国性回顾性队列研究
Jumpei Taniguchi and others
Journal of Antimicrobial Chemotherapy, Volume 80, Issue 8, August 2025, Pages 2194–2202
16
Oleanolic acid derivative bardoxolone combats multidrug-resistant Staphylococcus aureus by destroying cell membrane and pyruvate metabolism pathway
齐墩果酸衍生物巴多昔隆通过破坏细胞膜和丙酮酸代谢途径对抗多重耐药金黄色葡萄球菌
Yun-Dan Zheng and others
Journal of Antimicrobial Chemotherapy, Volume 80, Issue 8, August 2025, Pages 2203–2213
17
Evaluation of amoxicillin and benzylpenicillin therapy in early-onset neonatal sepsis: a pharmacometric external validation and simulation study
阿莫西林和苄青霉素治疗早期新生儿败血症的评估：一项药效计量学外部验证和模拟研究
Tom C Zwart and others
Journal of Antimicrobial Chemotherapy, Volume 80, Issue 8, August 2025, Pages 2214–2225
18
48Week body composition changes in persons with HIV switching to dolutegravir plus lamivudine: a planned subanalysis of the DOLAM randomized clinical trial
HIV感染者换用多替拉韦加拉米夫定治疗48周身体成分变化：DOLAM随机临床试验的计划子分析
Elisa de Lazzari and others
Journal of Antimicrobial Chemotherapy, Volume 80, Issue 8, August 2025, Pages 2226–2233
19
The impact of inter-infection time on antimicrobial resistance profiles in women with multiple urinary tract infections over time
多次尿路感染女性患者感染间隔时间对抗菌药物耐药性特征的影响
Trenton Honda and others
Journal of Antimicrobial Chemotherapy, Volume 80, Issue 8, August 2025, Pages 2234–2240
20
Development and evaluation of a novel rapid immunochromatographic assay for the detection of DHA-producing Enterobacterales
一种检测产DHA肠杆菌科细菌的新型快速免疫层析法的开发与评估
Christian Moguet and others
Journal of Antimicrobial Chemotherapy, Volume 80, Issue 8, August 2025, Pages 2241–2246
21
Enterococcus faecium bacteraemia: a multicentre observational study focused on risk factors for clinical and microbiological outcomes
粪肠球菌菌血症：一项关注临床和微生物学结局风险因素的多中心观察性研究
Matteo Rinaldi and others
Journal of Antimicrobial Chemotherapy, Volume 80, Issue 8, August 2025, Pages 2247–2256
22
Indolocarbazoles as host-directed therapeutics against intracellular infections by methicillin-resistant Staphylococcus aureus
靛红咔唑类化合物作为宿主导向疗法对抗甲氧西林耐药金黄色葡萄球菌细胞内感染
Robin H G A van den Biggelaar and others
Journal of Antimicrobial Chemotherapy, Volume 80, Issue 8, August 2025, Pages 2257–2268
23
Clinical validation of antimicrobial dosing regimens for continuous renal replacement therapy based on an ex vivo dosing algorithm
基于体外给药算法的连续性肾脏替代治疗抗菌药物给药方案的临床验证
Christina Koenig and others
Journal of Antimicrobial Chemotherapy, Volume 80, Issue 8, August 2025, Pages 2269–2279
24
Novel integrative and conjugative elements carrying cfr(B) and cfr(C) linezolid resistance genes in Clostridioides difficile isolates from calves, Italy
意大利牛犊艰难梭菌分离株中携带cfr(B)和cfr(C)利奈唑胺耐药基因的新型整合性和接合性元件
Andrea Brenciani and others
Journal of Antimicrobial Chemotherapy, Volume 80, Issue 8, August 2025, Pages 2280–2284
25
Characterization of Carbapenemase-producing Enterobacterales isolated from patients returning from Sub-Saharan Africa, France, 2015–2022
2015-2022年从撒哈拉以南非洲返回的法国患者中分离出的产碳青霉烯酶肠杆菌科细菌的特征
Corentin Poignon and others
Journal of Antimicrobial Chemotherapy, Volume 80, Issue 8, August 2025, Pages 2285–2294
26
Penicillin-susceptible ST398 with strong biofilm-forming ability poses a significant threat to osteoarticular infections
具有强生物膜形成能力的青霉素敏感ST398型对骨关节感染构成重大威胁
Ye Jin and others
Journal of Antimicrobial Chemotherapy, Volume 80, Issue 8, August 2025, Pages 2295–2304
27
Cardiac safety of bedaquiline, delamanid and moxifloxacin co-administered with or without varying doses of sutezolid or delpazolid for the treatment of drug-susceptible TB
贝达喹啉、德拉马尼和莫西沙星与不同剂量苏特唑利或德帕唑利联合用药治疗药物敏感型肺结核的心脏安全性
Simon E Koele and others
Journal of Antimicrobial Chemotherapy, Volume 80, Issue 8, August 2025, Pages 2305–2313
28
Comparison of ceftolozane/tazobactam and meropenem in treating bloodstream infections caused by extended-spectrum β-lactamase-producing Enterobacterales: a single-centre, retrospective, real-world study
头孢托唑坦/他唑巴坦与美罗培南治疗产超广谱β-内酰胺酶肠杆菌科细菌所致血流感染的对比：一项单中心回顾性现实研究
Dimitrios Basoulis and others
Journal of Antimicrobial Chemotherapy, Volume 80, Issue 8, August 2025, Pages 2314–2322
Research Letters(研究信件)
29
Dalbavancin as chronic suppressive therapy in a patient undergoing monthly apheresis: a case report with therapeutic drug monitoring
达巴万星作为每月进行血浆置换术患者的长期抑制治疗：一项带治疗药物监测的病例报告
Carlo Pallotto and others
Journal of Antimicrobial Chemotherapy, Volume 80, Issue 8, August 2025, Pages 2323–2324
30
A novel methicillin-resistant Staphylococcus aureus lineage (ST4174) with an uncharacterized SCCmec variant identified in Korean pigs
韩国猪体内发现的一种带有未表征SCCmec变体的新型甲氧西林耐药金黄色葡萄球菌谱系（ST4174）
Hyeonwoo Cho and Kun Taek Park
Journal of Antimicrobial Chemotherapy, Volume 80, Issue 8, August 2025, Pages 2325–2326
31
Time fixes everything, but not always: 10years of persistent PI mutations in the absence of pharmacological pressure—a case report
时间能治愈一切，但并非总是如此：无药物压力下持续10年的蛋白酶抑制剂突变——一例病例报告
Layla Pagnucco and others
Journal of Antimicrobial Chemotherapy, Volume 80, Issue 8, August 2025, Pages 2327–2330
32
Carbapenem resistance in Escherichia marmotae: characterization of IncL plasmids carrying blaOXA-48
土拨鼠埃希菌的碳青霉烯耐药性：携带blaOXA-48的IncL质粒特征
Astrid Rasmussen and others
Journal of Antimicrobial Chemotherapy, Volume 80, Issue 8, August 2025, Pages 2330–2331
Letters to the Editor(致编辑的信)
33
Comment on: Clinical outcomes and the impact of treatment modalities in children with carbapenem-resistant Enterobacteriaceae bloodstream infections: a retrospective cohort study from a tertiary university hospital
述评：产碳青霉烯酶肠杆菌科细菌血流感染患儿的临床预后和治疗方式的影响：一项来自三级大学医院的回顾性队列研究
Jianjun Li and others
Journal of Antimicrobial Chemotherapy, Volume 80, Issue 8, August 2025, Page 2332
34
Clinical outcomes and the impact of treatment modalities in children with carbapenem-resistant Enterobacteriaceae bloodstream infections: a retrospective cohort study from a Tertiary University Hospital—right to reply—author’s response
产碳青霉烯酶肠杆菌科细菌血流感染患儿的临床预后和治疗方式的影响：一项来自三级大学医院的回顾性队列研究——作者回复
Gulhadiye Avcu
Journal of Antimicrobial Chemotherapy, Volume 80, Issue 8, August 2025, Pages 2332–2333
Corrections(更正)
35
Correction to: Sofosbuvir as post-exposure prophylaxis for yellow fever–associated viscerotropic disease (YEL-AVD)
更正：索非布韦作为黄热病相关内脏热带病（YEL-AVD）暴露后预防用药
Journal of Antimicrobial Chemotherapy, Volume 80, Issue 8, August 2025, Page 2334
36
Correction to: Pandemic human-associated extended-spectrum β-lactamase-producing Escherichia coli lineages of ST38, ST131 and ST141 identified in Viennese dogs
更正：维也纳犬体内发现与人相关的大流行性产超广谱β-内酰胺酶大肠杆菌ST38、ST131和ST141谱系
Journal of Antimicrobial Chemotherapy, Volume 80, Issue 8, August 2025, Page 2335
37
Correction to: GP or ChatGPT? Ability of large language models (LLMs) to support general practitioners when prescribing antibiotics
更正：全科医生还是ChatGPT？大型语言模型（LLM）在全科医生开具抗生素处方时的辅助能力
Journal of Antimicrobial Chemotherapy, Volume 80, Issue 8, August 2025, Page 2336
Journal of Antimicrobial Chemotherapy, Volume 80, Issue Supplement_2
抗菌化疗杂志 80卷 增刊2期
https://academic.oup.com/jac/issue
SUPPLEMENT (补充)
CANWARD 2007-23
加拿大抗感染耐药监测项目（CANWARD）2007-2023年数据/报告
Foreword(前言)
1
The CANWARD studies: Canadian Antimicrobial Resistance Alliance (CARA) Canadian Hospital Ward Antibiotic Resistance Surveillance collection
加拿大抗感染耐药监测项目研究：加拿大抗微生物耐药联盟（CARA）加拿大医院病房耐药性监测数据集
James C Hurley and Jean-Yves Madec
Journal of Antimicrobial Chemotherapy, Volume 80, Issue Supplement_2, September 2025, Page ii1
Supplement Papers(补充论文)
2
Seventeen years of the CANWARD study (2007–23)
加拿大抗感染耐药监测项目研究17年（2007-2023年）
George G Zhanel and Heather J Adam
Journal of Antimicrobial Chemotherapy, Volume 80, Issue Supplement_2, September 2025, Pages ii2–ii4
3
Gram-positive pathogens from Canadian hospitals: 17years of results from the CANWARD study (2007–23)
来自加拿大医院的革兰氏阳性病原体：加拿大抗感染耐药监测项目研究的17年结果（2007-2023）
George G Zhanel and others
Journal of Antimicrobial Chemotherapy, Volume 80, Issue Supplement_2, September 2025, Pages ii5–ii14
4
Gram-negative pathogens from Canadian hospitals: 17 years of results from the CANWARD study (2007–23)
来自加拿大医院的革兰氏阴性病原体：加拿大抗感染耐药监测项目研究的17年结果（2007-2023）
George G Zhanel and others
Journal of Antimicrobial Chemotherapy, Volume 80, Issue Supplement_2, September 2025, Pages ii15–ii26
5
Characterization of methicillin-resistant Staphylococcus aureus in Canadian hospitals: 17 years of the CANWARD study (2007–23)
加拿大医院耐甲氧西林金黄色葡萄球菌的特征：加拿大抗感染耐药监测项目研究的17年（2007-2023）
Anissa Brahami and others
Journal of Antimicrobial Chemotherapy, Volume 80, Issue Supplement_2, September 2025, Pages ii27–ii34
6
Comparison of antimicrobial resistance and serotype patterns in Streptococcus pneumoniae from blood cultures and respiratory specimens in Canadian hospitals from the CANWARD study (2007–23)
加拿大抗感染耐药监测项目研究中加拿大医院血液培养和呼吸道标本中肺炎链球菌抗微生物药物耐药性和血清型的比较（2007-23）
Heather J Adam and others
Journal of Antimicrobial Chemotherapy, Volume 80, Issue Supplement_2, September 2025, Pages ii35–ii44
7
Increasing rates of ESBL-producing Escherichia coli and Klebsiella pneumoniae in Canadian Hospitals: 17 years of the CANWARD study, 2007–23
加拿大医院中产生ESBL的大肠杆菌和肺炎克雷伯菌的比率增加：加拿大抗感染耐药监测项目研究17年，2007-2023
Philippe Lagacé-Wiens and others
Journal of Antimicrobial Chemotherapy, Volume 80, Issue Supplement_2, September 2025, Pages ii45–ii53
8
Characterization of ertapenem-resistant Enterobacterales in Canadian hospitals: 17 years of the CANWARD study (2007–23)
加拿大医院耐厄他培宁肠杆菌的特征：17年的加拿大抗感染耐药监测项目研究（2007-23）
Laura F Mataseje and others
Journal of Antimicrobial Chemotherapy, Volume 80, Issue Supplement_2, September 2025, Pages ii54–ii61
9
Characterization of carbapenem-resistant Pseudomonas aeruginosa in Canadian hospitals: 6years of the CANWARD study (2018–23)
加拿大医院耐碳青霉烯假单胞菌的特征：6年的加拿大抗感染耐药监测项目研究（2018-23）
Melissa McCracken and others
Journal of Antimicrobial Chemotherapy, Volume 80, Issue Supplement_2, September 2025, Pages ii62–ii71
10
Distribution and antimicrobial susceptibility profile of pathogens recovered from the bloodstream of Canadian patients: results from the CANWARD study (2007–23)
加拿大患者血液中病原菌的分布和药敏特征：来自加拿大抗感染耐药监测项目研究（2007-23）的结果
Andrew Walkty and others
Journal of Antimicrobial Chemotherapy, Volume 80, Issue Supplement_2, September 2025, Pages ii72–ii82
Journal of Antimicrobial Chemotherapy Volume 80, Issue 9抗菌化疗杂志 80卷 9期
https://academic.oup.com/jac/issue
VIEWPOINT（观点）
1
Classifying patients with invasive fungal disease: towards a unified case definition?
侵袭性真菌病患者分类：能否达成统一的病例定义？
Mehmet Ergün and others
Journal of Antimicrobial Chemotherapy, Volume 80, Issue 9, September 2025, Pages 2337–2343,
SYSTEMATIC REVIEW（系统综述）
2
Efficacy and safety of earlier switching to an oral antibiotic therapy for the treatment of Gram-positive bloodstream infections: a systematic review and meta-analysis
早期转换为口服抗生素治疗革兰氏阳性菌血流感染的疗效和安全性：一项系统综述和荟萃分析
ZhaoYi Tan and others
Journal of Antimicrobial Chemotherapy, Volume 80, Issue 9, September 2025, Pages 2344–2360,
ORIGINAL RESEARCH（论著）
3
Determination of epidemiological cut-off values for Narasin, Salinomycin, Lasalocid and Monensin in Enterococcus faecium
屎肠球菌中那拉霉素、盐霉素、拉沙洛西钠和莫能菌素流行病学临界值的测定
Maria Laura Ferrando and others
Journal of Antimicrobial Chemotherapy, Volume 80, Issue 9, September 2025, Pages 2361–2368,
4
Persistence of CXCR4-tropic virus in people living with four-class drug-resistant HIV and its clinical impact in the modern antiretroviral era
四类耐药HIV感染者体内CXCR4嗜性病毒的持续存在及其在现代抗逆转录病毒治疗时代的临床影响
Rebecka Papaioannu Borjesson and others
Journal of Antimicrobial Chemotherapy, Volume 80, Issue 9, September 2025, Pages 2369–2374,
5
Hypertension and blood pressure changes with dolutegravir or comparator antiretroviral therapy in randomized trials through 96 weeks
随机试验中96周内使用多替拉韦或对照抗逆转录病毒疗法对高血压和血压变化的影响
Parul Patel and others
Journal of Antimicrobial Chemotherapy, Volume 80, Issue 9, September 2025, Pages 2375–2383,
6
Comparative analysis of lipid profile changes in treatment-naïve people living with HIV on INSTI-based single-tablet regimens, BIC/FTC/TAF and DTG/3TC: real-world evidence from South Korea
基于整合酶抑制剂的单片复方制剂BIC/FTC/TAF和DTG/3TC在韩国初治HIV感染者中血脂谱变化的比较分析：来自现实世界的证据
So Yun Lim and others
Journal of Antimicrobial Chemotherapy, Volume 80, Issue 9, September 2025, Pages 2384–2390,
7
A novel multilocus sequence typing scheme for Morganella spp.: population structure and introduction of quantitative metric for standardization of MLST scheme
摩根氏菌属的一种新型多位点序列分型方案：群体结构及引入用于标准化多位点序列分型方案的定量度量标准
Aymeric Jacquemin and others
Journal of Antimicrobial Chemotherapy, Volume 80, Issue 9, September 2025, Pages 2391–2398,
8
Genomic characterization of multidrug-resistant extended-spectrum β-lactamase-producing Vibrio cholerae O1 strains from 2022 cholera outbreak in Kenya
2022年肯尼亚霍乱疫情中产超广谱β-内酰胺酶的多重耐药霍乱弧菌O1株的基因组特征
Diana Imoli and others
Journal of Antimicrobial Chemotherapy, Volume 80, Issue 9, September 2025, Pages 2399–2407,
9
Impact of empiric anti-VRE therapy on survival in vancomycin-resistant enterococcal bloodstream infection
经验性抗万古霉素耐药肠球菌治疗对万古霉素耐药肠球菌血流感染患者生存率的影响
Tao-Hung Ou and others
Journal of Antimicrobial Chemotherapy, Volume 80, Issue 9, September 2025, Pages 2408–2416,
10
Safety of topical tobramycin powder during operative treatment of fractures
骨折手术中使用局部妥布霉素粉末的安全性
Gregory M Schrank and others
Journal of Antimicrobial Chemotherapy, Volume 80, Issue 9, September 2025, Pages 2417–2420,
11
Trimethoprim/sulfamethoxazole and risk of haemophagocytic lymphohistiocytosis (HLH): a literature review and disproportionality analysis using individual case safety reports from FAERS
复方磺胺甲恶唑与噬血细胞性淋巴组织细胞增多症（HLH）的风险：基于FAERS数据库个案安全报告的文献综述和比例失衡分析
Rinko Lau and others
Journal of Antimicrobial Chemotherapy, Volume 80, Issue 9, September 2025, Pages 2421–2427,
12
Highly drug-resistant Vibrio cholerae harbouring blaPER-7 isolated from travellers returning to England
从返回英国的旅行者中分离出携带blaPER-7基因的高度耐药霍乱弧菌
Satheesh Nair and others
Journal of Antimicrobial Chemotherapy, Volume 80, Issue 9, September 2025, Pages 2428–2432,
13
Overcoming antimicrobial resistance in Helicobacter pylori: the roles of collateral sensitivity and biofilm dynamics
克服幽门螺杆菌的抗菌药物耐药性：附带敏感性和生物膜动态的作用
Siddharth Singh and others
Journal of Antimicrobial Chemotherapy, Volume 80, Issue 9, September 2025, Pages 2433–2441,
14
Clinical and microbiological analysis of bloodstream infections by four cefiderocol-resistant and not previously exposed NDM-producing Klebsiella pneumoniae
四种未接触过但对头孢地尔耐药的产NDM肺炎克雷伯菌所致血流感染的临床和微生物学分析
Maria Mazzitelli and others
Journal of Antimicrobial Chemotherapy, Volume 80, Issue 9, September 2025, Pages 2442–2446,
15
Synergistic effects of DHA27 combined with gentamicin against methicillin-resistant Staphylococcus aureus in vitro and in vivo
DHA27与庆大霉素联合对耐甲氧西林金黄色葡萄球菌的体内外协同作用
Xuemin Chen and others
Journal of Antimicrobial Chemotherapy, Volume 80, Issue 9, September 2025, Pages 2447–2458,
16
A multicentre study for determination of epidemiological cut-off values for Candida auris with EUCAST broth microdilution reference methodology
采用EUCAST肉汤微量稀释参考方法进行耳念珠菌流行病学临界值的多中心测定研究
Joseph Meletiadis and others
Journal of Antimicrobial Chemotherapy, Volume 80, Issue 9, September 2025, Pages 2459–2465,
17
Impact of vancomycin resistance on attributable mortality among Enterococcus faecium bloodstream infections: propensity score analysis of a large, multicentre retrospective study
万古霉素耐药对屎肠球菌血流感染归因死亡率的影响：一项大型多中心回顾性研究的倾向评分分析
M Del Monte and others
Journal of Antimicrobial Chemotherapy, Volume 80, Issue 9, September 2025, Pages 2466–2473,
18
Dynamics of dual CMV and EBV co-reactivation and emergence of resistance in an HSCT recipient
异基因造血干细胞移植受者中CMV和EBV双重再激活的动态变化及耐药性的出现
Martyna Pociupany and others
Journal of Antimicrobial Chemotherapy, Volume 80, Issue 9, September 2025, Pages 2474–2483,
19
Antimicrobial use for the treatment of bacterial sexually transmitted infections among doxycycline post-exposure prophylaxis (DoxyPEP) users in Milan, Italy
意大利米兰多西环素暴露后预防（DoxyPEP）使用者中用于治疗细菌性性传播感染的抗菌药物使用情况
Angelo Roberto Raccagni and others
Journal of Antimicrobial Chemotherapy, Volume 80, Issue 9, September 2025, Pages 2484–2486,
20
Comparing the mortality of patients with sepsis using empirical piperacillin/tazobactam and cefepime: analysis of the MIMIC-IV database
使用经验性哌拉西林/他唑巴坦和头孢吡肟的脓毒症患者死亡率比较：基于MIMIC-IV数据库的分析
Yongseop Lee and others
Journal of Antimicrobial Chemotherapy, Volume 80, Issue 9, September 2025, Pages 2487–2495,
21
Transmitted drug resistance profiles among people living with HIV-1 in Henan province, China, 2024
2024年中国河南省HIV-1感染者传播耐药情况
Jinjin Liu and others
Journal of Antimicrobial Chemotherapy, Volume 80, Issue 9, September 2025, Pages 2496–2502,
22
Fluctuations in copy number of the class A carbapenemase gene blaFRI appear to confer high-level carbapenem resistance
A类碳青霉烯酶基因blaFRI拷贝数的波动似乎赋予了高水平碳青霉烯耐药性
Makiko Noda and others
Journal of Antimicrobial Chemotherapy, Volume 80, Issue 9, September 2025, Pages 2503–2512,
23
In vitro activity of ceftobiprole plus ampicillin against Enterococcus faecalis causing infective endocarditis: phenotypic and genotypic characterization
头孢比罗联合氨苄西林对引起感染性心内膜炎的粪肠球菌的体外活性：表型和基因型特征
Clara Moretó-Castellsaguéand others
Journal of Antimicrobial Chemotherapy, Volume 80, Issue 9, September 2025, Pages 2513–2523,
24
Paradoxical interaction between dalbavancin and β-lactams against endocarditis-associated Enterococcus faecalis clinical isolates
达巴万星与β-内酰胺类药物对心内膜炎相关粪肠球菌临床分离株的矛盾相互作用
David Luque Paz and others
Journal of Antimicrobial Chemotherapy, Volume 80, Issue 9, September 2025, Pages 2524–2529,
25
Comparative evaluation of broth microdilution and gradient diffusion methods in Burkholderia cepacia complex susceptibility testing: implications of transitioning to ECV-based interpretation
伯克霍尔德菌复合群药敏试验中肉汤微量稀释法和梯度扩散法的比较评估：向基于ECV解释转变的影响
Wenjie Cui and others
Journal of Antimicrobial Chemotherapy, Volume 80, Issue 9, September 2025, Pages 2530–2540,
26
Strengthening antimicrobial resistance diagnostics in National Reference Laboratories across One Health in South and Southeast Asia: impact of external quality assessment and targeted follow-up
加强南亚和东南亚“同一健康”国家参考实验室的抗菌药物耐药性诊断能力：外部质量评估和针对性随访的影响
Freshwork Ayalew Abegaz and others
Journal of Antimicrobial Chemotherapy, Volume 80, Issue 9, September 2025, Pages 2541–2549,
RESEARCH LETTERS（研究快信）
27
TDM-guided meropenem/vaborbactam-based therapy for successful treatment of intra-abdominal and bloodstream infection caused by KPC-producing ceftazidime/avibactam-resistant Klebsiella pneumoniae in a paediatric liver transplant recipient
治疗药物监测指导下的美罗培南/瓦博巴坦疗法成功治疗儿童肝移植受者中产KPC且对头孢他啶/阿维巴坦耐药的肺炎克雷伯菌引起的腹腔和血流感染
Giovanni Mulé and others
Journal of Antimicrobial Chemotherapy, Volume 80, Issue 9, September 2025, Pages 2550–2552,
28
Novel tmexC7D2-toprJ5 gene cluster and transposon Tn7759 carrying blaVIM-2 and blaOXA-10 genes in a carbapenem-resistant Pseudomonas putida from urban sewage
城市污水中碳青霉烯耐药恶臭假单胞菌中携带blaVIM-2和blaOXA-10基因的新型tmexC7D2-toprJ5基因簇和转座子Tn7759
Xinyuan Qiu and others
Journal of Antimicrobial Chemotherapy, Volume 80, Issue 9, September 2025, Pages 2552–2555,
29
Characterization of multiresistance gene optrA in Bacillus subtillis from China
中国枯草芽孢杆菌中多重耐药基因optrA的特征分析
Yongliang Che and others
Journal of Antimicrobial Chemotherapy, Volume 80, Issue 9, September 2025, Pages 2555–2557,
30
Genomic characterization of a multidrug-resistant Mammaliicoccus sciuri strain isolated from urine of a patient from China
从中国患者尿液中分离出的一株多重耐药马氏鼠球菌的基因组特征
Fuqiang Ye and others
Journal of Antimicrobial Chemotherapy, Volume 80, Issue 9, September 2025, Pages 2558–2560,
LETTERS TO THE EDITOR（致编辑的信）
31
Comment on: Isavuconazole therapeutic drug monitoring and association with adverse events
关于“艾沙康唑治疗药物监测及其与不良反应的关联”的评论
Mi Zhou and others
Journal of Antimicrobial Chemotherapy, Volume 80, Issue 9, September 2025, Pages 2561–2562,
32
Comment on: Outcomes of ceftriaxone 2 g versus 1 g daily in hospitalised patients with pneumonia: a nationwide retrospective cohort study
关于“住院肺炎患者每日2克与1克头孢曲松疗效比较：一项全国性回顾性队列研究”的评论
Satoru Mitsuboshi
Journal of Antimicrobial Chemotherapy, Volume 80, Issue 9, September 2025, Page 2563,
33
Outcomes of ceftriaxone 2 g versus 1 g daily in hospitalized patients with pneumonia: a nationwide retrospective cohort study—authors’ response
住院肺炎患者每日2克与1克头孢曲松疗效比较：一项全国性回顾性队列研究——作者回复
Jumpei Taniguchi and others
Journal of Antimicrobial Chemotherapy, Volume 80, Issue 9, September 2025, Pages 2563–2564,
Journal of Antimicrobial Chemotherapy Volume 80, Issue 10抗菌化疗杂志 80卷 10期
https://academic.oup.com/jac/issue
REVIEWS（综述）
1
Long-acting cabotegravir and rilpivirine for the treatment of people with HIV: current landscape and challenges ahead
长效卡博特韦和利匹韦林治疗HIV感染者的现状与未来挑战
Luis Buzón-Martín and others
Journal of Antimicrobial Chemotherapy, Volume 80, Issue 10, October 2025, Pages 2565–2586,
2
Systematic reviews and the Journal of Antimicrobial Chemotherapy; past, present and future. A systematic reappraisal
系统综述与《抗菌化疗杂志》：过去、现在与未来——系统再评估
James C Hurley
Journal of Antimicrobial Chemotherapy, Volume 80, Issue 10, October 2025, Pages 2587–2596,
SYSTEMATIC REVIEWS（系统综述）
3
Studying intrapulmonary pharmacokinetics for tuberculosis treatment: a systematic review of methodology
研究肺结核治疗的肺内药代动力学：方法学的系统综述
Isabella van der Feltz and others
Journal of Antimicrobial Chemotherapy, Volume 80, Issue 10, October 2025, Pages 2597–2608,
4
Global prevalence of nitrofurantoin-resistant uropathogenic Escherichia coli (UPEC) in humans: a systematic review and meta-analysis
全球人类中耐呋喃妥因的尿路致病性大肠埃希菌（UPEC）流行率：系统综述与荟萃分析
Christopher Larkin and others
Journal of Antimicrobial Chemotherapy, Volume 80, Issue 10, October 2025, Pages 2609–2621,
ORIGINAL RESEARCH（研究论著）
5
Is ampicillin plus cephalosporins a therapeutic option for Ampicillin-Susceptible Enterococcus faecium?
氨苄青霉素联合头孢菌素是否为氨苄青霉素敏感的粪肠球菌的治疗选择？
Paula Bierge and others
Journal of Antimicrobial Chemotherapy, Volume 80, Issue 10, October 2025, Pages 2622–2629,
6
Therapeutic efficacy monitoring of pyronaridine–artesunate (Pyramax®) in treating uncomplicated Plasmodium falciparum malaria in Gia Lai province, Vietnam from 2022 to 2023
2022-2023年越南嘉莱省青蒿琥酯-吡咯尼抗（Pyramax®）用于无并发症恶性疟原虫疟疾的治疗效果监测
Nguyen Van Thanh and others
Journal of Antimicrobial Chemotherapy, Volume 80, Issue 10, October 2025, Pages 2630–2634,
7
Effectiveness of piperacillin/tazobactam loading dose for extended infusion dosing among patients with Gram-negative bacteraemia
哌拉西林/他唑巴坦负荷剂量用于革兰氏阴性菌血症患者延长输注给药的有效性
Savan Patel and others
Journal of Antimicrobial Chemotherapy, Volume 80, Issue 10, October 2025, Pages 2635–2643,
8
Intrapulmonary concentrations of ceftobiprole high doses administered by continuous infusion in critically ill patients with community-acquired pneumonia
连续输注大剂量头孢比罗在社区获得性肺炎危重患者中的肺内浓度
Claire Roger and others
Journal of Antimicrobial Chemotherapy, Volume 80, Issue 10, October 2025, Pages 2644–2653,
9
Cefixime versus benzathine penicillin G for the treatment of early syphilis—a randomized, controlled open label trial
头孢克肟与苄星青霉素G治疗早期梅毒的随机对照开放标签试验
Tamara Klementová and others
Journal of Antimicrobial Chemotherapy, Volume 80, Issue 10, October 2025, Pages 2654–2658,
10
Trends in antifungal use among hospitalized patients in the USA, 2018–23
2018-2023年美国住院患者抗真菌药物使用趋势
Dallas J Smith and others
Journal of Antimicrobial Chemotherapy, Volume 80, Issue 10, October 2025, Pages 2659–2664,
11
Clinical impact of the BCID2 and rapid AST VITEK® REVEALTM on antibiotic optimisation in critically ill patients with Gram-negative bloodstream infections: a quasi-experimental pre/post interventional study
BCID2和快速AST VITEK® REVEALTM对革兰氏阴性菌血流感染危重患者抗生素优化的临床影响：一项准实验性前后干预研究
Louis Oudiane and others
Journal of Antimicrobial Chemotherapy, Volume 80, Issue 10, October 2025, Pages 2665–2675,
12
In vitro activity of thiamphenicol against drug-susceptible and drug-resistant strains of Mycoplasma genitalium
甲砜霉素对药物敏感和耐药生殖支原体菌株的体外活性
Sofie Skovmand and others
Journal of Antimicrobial Chemotherapy, Volume 80, Issue 10, October 2025, Pages 2676–2681,
13
A priori optimization of levofloxacin dose regimen based on a population pharmacokinetics model
基于群体药代动力学模型的左氧氟沙星剂量方案先验优化
Emmanuel Enard and others
Journal of Antimicrobial Chemotherapy, Volume 80, Issue 10, October 2025, Pages 2682–2692,
14
Model-informed individualized administration of ceftazidime–avibactam in critically ill patients: population pharmacokinetics studies and a parametric time-to-event analysis
危重患者头孢他啶-阿维巴坦的模型知情个体化给药：群体药代动力学研究和参数时间事件分析
Tingting Wu and others
Journal of Antimicrobial Chemotherapy, Volume 80, Issue 10, October 2025, Pages 2693–2704,
15
Development of blood culture time-to-positivity as a pharmacodynamic indicator for monitoring antibiotic therapy against MDR Gram-negative bacteria
开发血培养阳性时间作为监测针对多重耐药革兰氏阴性菌抗生素治疗的药效动力学指标
Irene Zaghi and others
Journal of Antimicrobial Chemotherapy, Volume 80, Issue 10, October 2025, Pages 2705–2713,
16
In vivo activity of ceftibuten-ledaborbactam oral combination against serine-β-lactamase-producing Enterobacterales: an assessment in the pyelonephritis and cystitis murine model
头孢布坦-莱达博巴坦口服联合用药对产丝氨酸-β-内酰胺酶肠杆菌科细菌的体内活性评估：在肾盂肾炎和膀胱炎小鼠模型中的评估
Christina Koenig and others
Journal of Antimicrobial Chemotherapy, Volume 80, Issue 10, October 2025, Pages 2714–2718,
17
Faecal pharmacokinetics, microbiome, and bile acid changes in healthy subjects given intravenous followed by oral omadacycline; a Phase 1 clinical trial
健康受试者静脉注射后口服奥马环素的粪便药代动力学、微生物组和胆汁酸变化：一项1期临床试验
Jinhee Jo and others
Journal of Antimicrobial Chemotherapy, Volume 80, Issue 10, October 2025, Pages 2719–2726,
18
Interlaboratory comparison of a dried blood spot assay for antiretroviral adherence: implications for clinical application
抗逆转录病毒治疗依从性干血斑检测法的实验室间比对：对临床应用的启示
Nathan Engel and others
Journal of Antimicrobial Chemotherapy, Volume 80, Issue 10, October 2025, Pages 2727–2731,
19
A multicentre real-life prospective cohort study on effectiveness, durability and safety of long-acting injectable cabotegravir and rilpivirine in northern Italy: the LONGITUDE study
意大利北部长效注射用卡博特韦和利匹韦林有效性、持久性和安全性的现实中多中心前瞻性队列研究：LONGITUDE研究
Maria Mazzitelli and others
Journal of Antimicrobial Chemotherapy, Volume 80, Issue 10, October 2025, Pages 2732–2741,
20
Assessment of the risk of developing cefepime-induced abnormal liver enzyme levels using the albumin–bilirubin score and fibrosis-4 index: a single-centre retrospective case–control study
使用白蛋白-胆红素评分和纤维化-4指数评估头孢吡肟诱导的肝酶水平异常发生风险：一项单中心回顾性病例对照研究
Hiroki Katsu and others
Journal of Antimicrobial Chemotherapy, Volume 80, Issue 10, October 2025, Pages 2742–2751,
21
Clinical course of patients with bloodstream infections enrolled in the BALANCE clinical trial
BALANCE临床试验中血流感染患者的临床病程
Sean W X Ong and others
Journal of Antimicrobial Chemotherapy, Volume 80, Issue 10, October 2025, Pages 2752–2758,
22
Comparative outcomes of polymyxins in neurocritical care patients with carbapenem-resistant Gram-negative bacterial pneumonia: a retrospective cohort study
神经重症患者中多黏菌素治疗碳青霉烯类耐药革兰氏阴性菌肺炎的结果比较：一项回顾性队列研究
Qian Zeng and others
Journal of Antimicrobial Chemotherapy, Volume 80, Issue 10, October 2025, Pages 2759–2772,
23
Distinct population structure and genomic context of NarAB between broiler and human clinical Enterococcus isolates
肉鸡和人类临床分离的粪肠球菌中NarAB的不同群体结构和基因组背景
Jayanth Balakuntla and others
Journal of Antimicrobial Chemotherapy, Volume 80, Issue 10, October 2025, Pages 2773–2781,
24
Population pharmacokinetics of bictegravir in real-world people with HIV
现实中HIV感染者比克替拉韦的群体药代动力学
Pierre Ekobena and others
Journal of Antimicrobial Chemotherapy, Volume 80, Issue 10, October 2025, Pages 2782–2789,
25
Rifampicin concentrations throughout the entire treatment duration of active tuberculosis; impact of sex and body mass index
活动性肺结核整个治疗期间利福平浓度：性别和体重指数的影响
Teres Samuelsson and others
Journal of Antimicrobial Chemotherapy, Volume 80, Issue 10, October 2025, Pages 2790–2798,
26
Performance of disc diffusion and gradient strip test on different Mueller–Hinton agar media plates and ComASP® and Bruker UMIC® Cefiderocol Microdilution Panels for cefiderocol susceptibility testing in carbapenem-resistant Pseudomonas aeruginosa
在碳青霉烯类耐药铜绿假单胞菌中对头孢地尔敏感性测试使用不同穆勒-欣顿琼脂培养基平板和ComASP®及Bruker UMIC®头孢地尔微量稀释板的纸片扩散法和梯度条带测试的性能
Stefano Mancini and others
Journal of Antimicrobial Chemotherapy, Volume 80, Issue 10, October 2025, Pages 2799–2806,
27
Placental transfer of medications to treat COVID-19, molnupiravir, favipiravir and nirmatrelvir/ritonavir, in the ex vivo human cotyledon model
在离体人类绒毛叶模型中治疗COVID-19的药物莫努匹拉韦、法维拉韦和奈玛特韦/利托那韦的胎盘转移
Solene Labaye and others
Journal of Antimicrobial Chemotherapy, Volume 80, Issue 10, October 2025, Pages 2807–2813,
28
Synergistic cefiderocol-containing antibiotic combinations active against highly drug-resistant Acinetobacter baumannii patient isolates with diverse resistance mechanisms
针对具有多种耐药机制的高度耐药鲍曼不动杆菌患者分离株的含头孢地尔抗生素联合用药的协同作用
Justin Halim and others
Journal of Antimicrobial Chemotherapy, Volume 80, Issue 10, October 2025, Pages 2814–2824,
29
Uptake of drug-reduced antiretroviral strategies and impact on costs over 2015–22: experience from an HIV clinic in Paris, France
2015-2022年药物减量抗逆转录病毒策略的采用情况及对成本的影响：来自法国巴黎一家HIV诊所的经验
L Sagaon-Teyssier and others
Journal of Antimicrobial Chemotherapy, Volume 80, Issue 10, October 2025, Pages 2825–2833,
30
Molecular characterization of fluoroquinolone resistance in invasive clinical isolates of Streptococcus pneumoniae susceptible to delafloxacin
对达拉氟沙星敏感的侵袭性临床肺炎链球菌分离株中氟喹诺酮耐药性的分子特征
Emilia Cercenado and others
Journal of Antimicrobial Chemotherapy, Volume 80, Issue 10, October 2025, Pages 2834–2843,
31
Genomic structure of class 1 and 2 integrons in non-typhoidal Salmonella isolated from food animals and related meat products in the USA
美国食品动物及其相关肉类产品中分离的非伤寒沙门氏菌1类和2类整合子的基因组结构
Chih-Hao Hsu and others
Journal of Antimicrobial Chemotherapy, Volume 80, Issue 10, October 2025, Pages 2844–2853,
32
Characterization of blaOXA-542-mediated carbapenem resistance in Acinetobacter baumannii
鲍曼不动杆菌中blaOXA-542介导的碳青霉烯类耐药性的特征
Jingchen Hao and others
Journal of Antimicrobial Chemotherapy, Volume 80, Issue 10, October 2025, Pages 2854–2861,
33
Phenotypic and genotypic profiles of clinical isolates of various Nocardia species to carbapenems and fluoroquinolones
各种诺卡氏菌属临床分离株对碳青霉烯类和氟喹诺酮类的表型和基因型特征
Jing Yang and others
Journal of Antimicrobial Chemotherapy, Volume 80, Issue 10, October 2025, Pages 2862–2872,
RESEARCH LETTERS（研究快报）
34
Oritavancin in a patient with recurrent endocarditis by Enterococcus faecalis: a new therapeutic option?
奥利他万星治疗粪肠球菌复发性心内膜炎患者：一种新的治疗选择？
Giulia Turicchi and Marco Bongiovanni
Journal of Antimicrobial Chemotherapy, Volume 80, Issue 10, October 2025, Pages 2873–2874,
35
The catA1 chloramphenicol resistance gene originated in Atlantibacter hermannii
catA1氯霉素耐药基因起源于大西洋菌属赫尔曼尼菌
Robert A Moran and Ruth M Hall
Journal of Antimicrobial Chemotherapy, Volume 80, Issue 10, October 2025, Pages 2874–2876,
36
Horizontal transmission of a multidrug-resistant IncM1 plasmid harbouring blaOXA-48 and blaCTX-M-14b among patient microbiotas
携带blaOXA-48和blaCTX-M-14b的多重耐药IncM1质粒在患者微生物群中的水平传播
Roberto Sierra and others
Journal of Antimicrobial Chemotherapy, Volume 80, Issue 10, October 2025, Pages 2876–2879,
37
Antimicrobial activity of temocillin on ceftriaxone-resistant and ceftriaxone-susceptible isolates of Neisseria gonorrhoeae
替莫西林对头孢曲松耐药和头孢曲松敏感淋病奈瑟菌分离株的抗菌活性
Julie Brousseau and others
Journal of Antimicrobial Chemotherapy, Volume 80, Issue 10, October 2025, Pages 2879–2881,
LETTERS TO THE EDITOR（致编辑的信）
38
Comment on: Bactericidal activity of antibiotic combinations against clinical isolates of Enterococcus gallinarum and Enterococcus casseliflavus
述评：抗生素联合用药对临床分离的鸡肠球菌和粪肠球菌的杀菌活性
Karl Oldberg and Magnus Rasmussen
Journal of Antimicrobial Chemotherapy, Volume 80, Issue 10, October 2025, Pages 2882–2883,
39
Comment on: Outcomes of ceftriaxone 2 g versus 1 g daily in hospitalized patients with pneumonia: a nationwide retrospective cohort study
述评：住院肺炎患者每日2克与1克头孢曲松的疗效：一项全国性回顾性队列研究
Giancarlo Ceccarelli and others
Journal of Antimicrobial Chemotherapy, Volume 80, Issue 10, October 2025, Pages 2884–2885,
40
Outcomes of ceftriaxone 2 g versus 1 g daily in hospitalized patients with pneumonia: a nationwide retrospective cohort study—right to reply—authors’ response
住院肺炎患者每日2克与1克头孢曲松的疗效：一项全国性回顾性队列研究——作者回应权——作者回复
Jumpei Taniguchi and others
Journal of Antimicrobial Chemotherapy, Volume 80, Issue 10, October 2025, Pages 2885–2886,
Journal of Antimicrobial Chemotherapy Volume 80, Issue Supplement_4抗菌化疗杂志 80卷 增刊4期
https://academic.oup.com/jac/issue/80/Supplement_4
SUPPLEMENT（补充）
Two Decades of BSAC Resistance Surveillance
英国抗菌化疗学会二十年耐药性监测
FOREWORD（前言）
1
Two Decades of BSAC Resistance Surveillance
英国抗菌化疗学会二十年耐药性监测
James C Hurley and Alan P Johnson
Journal of Antimicrobial Chemotherapy, Volume 80, Issue Supplement_4, October 2025, Page iv1,
SUPPLEMENT PAPERS（补充论文）
2
Two decades of resistance surveillance by the British Society for Antimicrobial Chemotherapy: design, development, delivery, deficiencies and future directions
英国抗菌化疗学会二十年耐药性监测：设计、发展、实施、不足与未来方向
Alasdair P MacGowan and others
Journal of Antimicrobial Chemotherapy, Volume 80, Issue Supplement_4, October 2025, Pages iv2–iv6,
3
The British Society for Antimicrobial Chemotherapy Resistance Surveillance Project: methods and limitations
英国抗菌化疗学会耐药性监测项目：方法与局限性
Michael Allen and others
Journal of Antimicrobial Chemotherapy, Volume 80, Issue Supplement_4, October 2025, Pages iv7–iv21,
4
Antimicrobial resistance among Gram-positive agents of bacteraemia in the UK and Ireland: trends from 2001 to 2019
英国和爱尔兰地区革兰氏阳性菌血流感染病原体的抗菌药物耐药性趋势（2001 - 2019年）
Rosy Reynolds and others
Journal of Antimicrobial Chemotherapy, Volume 80, Issue Supplement_4, October 2025, Pages iv22–iv35,
5
Antimicrobial resistance among Gram-negative agents of bacteraemia in the UK and Ireland: trends from 2001 to 2019
英国和爱尔兰地区革兰氏阴性菌血流感染病原体的抗菌药物耐药性趋势（2001 - 2019年）
Rosy Reynolds and others
Journal of Antimicrobial Chemotherapy, Volume 80, Issue Supplement_4, October 2025, Pages iv36–iv48,
6
Antimicrobial resistance among agents of hospital-acquired lower respiratory tract infection in the UK and Ireland: trends from 2008/2009 to 2018/2019
英国和爱尔兰地区医院获得性下呼吸道感染病原体的抗菌药物耐药性趋势（2008/2009 - 2018/2019年）
Rosy Reynolds and others
Journal of Antimicrobial Chemotherapy, Volume 80, Issue Supplement_4, October 2025, Pages iv49–iv59,
7
Antimicrobial resistance among agents of community-associated lower respiratory tract infection in the UK and Ireland: trends from 1999/2000 to 2018/2019
英国和爱尔兰地区社区获得性下呼吸道感染病原体的抗菌药物耐药性趋势（1999/2000 - 2018/2019年）
Rosy Reynolds and others
Journal of Antimicrobial Chemotherapy, Volume 80, Issue Supplement_4, October 2025, Pages iv60–iv71,
8
Trends of serotypes and resistance among Streptococcus pneumoniae in the UK and Ireland (1999–2019)
英国和爱尔兰地区肺炎链球菌血清型及耐药性趋势（1999 - 2019年）
Carolyne Horner and others
Journal of Antimicrobial Chemotherapy, Volume 80, Issue Supplement_4, October 2025, Pages iv72–iv86,
9
Applications and benefits of the British Society for Antimicrobial Chemotherapy Resistance Surveillance Project—legacy and future
英国抗菌化疗学会耐药性监测项目的应用与益处——成果与未来
Benjamin J Parcell and others
Journal of Antimicrobial Chemotherapy, Volume 80, Issue Supplement_4, October 2025, Pages iv87–iv95,
Journal of Antimicrobial Chemotherapy Volume 80, Issue 11抗菌化疗杂志 80卷 11期
https://academic.oup.com/jac/issue
VIEWPOINTS（观点）
1
Modification of antimicrobial susceptibility testing methods
抗菌药物敏感性检测方法的修改
Ian Morrissey and Jean B Patel
Journal of Antimicrobial Chemotherapy, Volume 80, Issue 11, November 2025, Pages 2887–2888,
2
Viewpoint: global antimicrobial stewardship accreditation is needed: the experience in Kentucky, USA
观点：需要建立全球抗菌药物管理认证体系：美国肯塔基州的经验
Ashley M Wilde and others
Journal of Antimicrobial Chemotherapy, Volume 80, Issue 11, November 2025, Pages 2889–2891,
REVIEWS（综述）
3
Phages connect the biological dots of antimicrobial resistance: from genesis and spread to alternative treatment modules
噬菌体揭示抗菌药物耐药性的生物学脉络：从起源与传播到替代治疗模式
Cleo Anastassopoulou and others
Journal of Antimicrobial Chemotherapy, Volume 80, Issue 11, November 2025, Pages 2892–2901,
4
Molecular drivers of fusion plasmid: mechanistic insights and evolutionary implications
融合质粒的分子驱动因素：机制见解与进化意义
Ziyi Liu and others
Journal of Antimicrobial Chemotherapy, Volume 80, Issue 11, November 2025, Pages 2902–2911,
ORIGINAL RESEARCH（研究论著）
5
Emergence of livestock-associated MRSA clonal complex 398 in Thailand’s swine industry
泰国养猪业中出现与牲畜相关的MRSA克隆复合体398
Pawarut Narongpun and others
Journal of Antimicrobial Chemotherapy, Volume 80, Issue 11, November 2025, Pages 2912–2917,
6
Peripheral neuropathy during long-term suppressive therapy with tedizolid: a case series
长期使用替达拉韦抑制治疗期间出现周围神经病变：系列病例报告
Tomaso Beringheli and others
Journal of Antimicrobial Chemotherapy, Volume 80, Issue 11, November 2025, Pages 2918–2922,
7
Low bacterial metabolism as a central mechanism of antimicrobial resistance and potential therapeutic target of staphylococcal biofilms in ventricular assist device driveline infections
细菌低代谢作为抗菌药物耐药性的核心机制及心室辅助装置驱动线感染中葡萄球菌生物膜的潜在治疗靶点
Yao Sun and others
Journal of Antimicrobial Chemotherapy, Volume 80, Issue 11, November 2025, Pages 2923–2933,
8
The pivotal role of acnA in linking carbon metabolism to virulence and antimicrobial resistance in methicillin-resistant Staphylococcus aureus
acnA在连接碳代谢与耐甲氧西林金黄色葡萄球菌的毒力和抗菌药物耐药性中的关键作用
Jiahui Li and others
Journal of Antimicrobial Chemotherapy, Volume 80, Issue 11, November 2025, Pages 2934–2944,
9
Pharmacokinetics of rifampicin and isoniazid in patients with HIV–tuberculosis coinfection receiving efavirenz-based antiretroviral treatment: an ANRS12292–RIFAVIRENZ sub-study
接受以依非韦伦为基础的抗逆转录病毒治疗的HIV-结核病共感染患者中利福平和异烟肼的药代动力学：ANRS12292-RIFAVIRENZ子研究
Thibaut Gelé and others
Journal of Antimicrobial Chemotherapy, Volume 80, Issue 11, November 2025, Pages 2945–2953,
10
Novel mutations associated with clofazimine resistance in Mycobacterium intracellulare
胞内分枝杆菌中与氯法齐明耐药相关的新型突变
Xiuzhi Jiang and others
Journal of Antimicrobial Chemotherapy, Volume 80, Issue 11, November 2025, Pages 2954–2957,
11
Physiologically informed in vitro framework reveals context-dependent combinatory activity of niclosamide–colistin against Gram-negative bacteria
基于生理信息的体外框架揭示了针对革兰氏阴性菌的硝基咪唑-多粘菌素组合的情境依赖性活性
Mariana Romero-Gonzalez and others
Journal of Antimicrobial Chemotherapy, Volume 80, Issue 11, November 2025, Pages 2958–2969,
12
In vitro evolution provides insights into mechanisms of Mycoplasma genitalium resistance to moxifloxacin
体外进化揭示生殖支原体对莫西沙星的耐药机制
Teck-Phui Chua and others
Journal of Antimicrobial Chemotherapy, Volume 80, Issue 11, November 2025, Pages 2970–2977,
13
The toxin–antitoxin system SavRS contributes to vancomycin resistance in vancomycin-intermediate Staphylococcus aureus by mediating cell wall thickening
毒素-抗毒素系统SavRS通过介导细胞壁增厚促进万古霉素中间型金黄色葡萄球菌对万古霉素的耐药性
Weifeng Xu and others
Journal of Antimicrobial Chemotherapy, Volume 80, Issue 11, November 2025, Pages 2978–2988,
14
Molecular insights into carbapenemase-producing Enterobacterales from Senegal
塞内加尔产碳青霉烯酶肠杆菌目细菌的分子特征
Ousmane Sow and others
Journal of Antimicrobial Chemotherapy, Volume 80, Issue 11, November 2025, Pages 2989–3000,
15
Population pharmacokinetic model of linezolid and its metabolite PNU-142300 in elderly patients
老年患者中利奈唑胺及其代谢产物PNU-142300的群体药代动力学模型
Xianglong Chen and others
Journal of Antimicrobial Chemotherapy, Volume 80, Issue 11, November 2025, Pages 3001–3010,
16
In vitro activity of contezolid and other comparators against clinical Staphylococcus and Enterococcus: a multicenter study in China
在中国开展的一项多中心研究中，康替唑胺及其他对照药物对临床分离的金黄色葡萄球菌和肠球菌的体外活性
Rongqi Lu and others
Journal of Antimicrobial Chemotherapy, Volume 80, Issue 11, November 2025, Pages 3011–3020,
17
Co-existence of the oxazolidinone resistance genes cfr and optrA on a novel multiresistance plasmid from a methicillin-resistant Macrococcoides bohemicum strain
从一株耐甲氧西林的马科考代菌属波希米亚菌株中发现的携带恶唑烷酮耐药基因cfr和optrA的新型多重耐药质粒
Yao Zhu and others
Journal of Antimicrobial Chemotherapy, Volume 80, Issue 11, November 2025, Pages 3021–3025,
18
Multidrug resistance and recurrence in urinary bacteraemia among cancer patients
癌症患者中尿路菌血症的多药耐药性和复发情况
Ignacio Grafia and others
Journal of Antimicrobial Chemotherapy, Volume 80, Issue 11, November 2025, Pages 3026–3033,
19
Rapid replacement of blaKPC variant in ST11 carbapenem-resistant and hypervirulent Klebsiella pneumoniae contributed to ceftazidime/avibactam resistance during severe in vivo infection
在严重的体内感染期间，ST11型碳青霉烯耐药且高毒力的肺炎克雷伯菌中blaKPC变体的快速替代导致头孢他啶/阿维巴坦耐药
Ping Yang and others
Journal of Antimicrobial Chemotherapy, Volume 80, Issue 11, November 2025, Pages 3034–3042,
20
Potential human health risk of carbapenem-non-susceptible Pseudomonas aeruginosa from companion animals
伴侣动物中碳青霉烯类不敏感铜绿假单胞菌对人类健康的潜在风险
Jirachaya Toyting-Hiraishi and others
Journal of Antimicrobial Chemotherapy, Volume 80, Issue 11, November 2025, Pages 3043–3056,
21
Assessment of an LC coupled with tandem MS (LC-MS/MS) tool in the detection of antimicrobial resistance mechanisms in Enterobacterales
液相色谱-串联质谱（LC-MS/MS）工具在检测肠杆菌目细菌抗菌药物耐药机制中的应用评估
Anna Witkowska and others
Journal of Antimicrobial Chemotherapy, Volume 80, Issue 11, November 2025, Pages 3057–3064,
22
Multidrug efflux pumps and innate azole resistance of Mucor lusitanicus
毛霉属葡萄牙菌的多药外排泵及其固有唑类耐药性
Stephanie Toepfer and others
Journal of Antimicrobial Chemotherapy, Volume 80, Issue 11, November 2025, Pages 3065–3078,
23
Ivermectin dosing for children under 2 years
2岁以下儿童的伊维菌素剂量
Wenyu Yang and others
Journal of Antimicrobial Chemotherapy, Volume 80, Issue 11, November 2025, Pages 3079–3081,
24
Effectiveness of first-line lamivudine/dolutegravir antiretroviral therapy in persons with HIV: real-life data from the ICONA Foundation cohort
一线拉米夫定/多替拉韦抗逆转录病毒疗法在HIV感染者中的有效性：来自ICONA基金会队列的现实数据
Alessandra Vergori and others
Journal of Antimicrobial Chemotherapy, Volume 80, Issue 11, November 2025, Pages 3082–3091,
25
Eligibility and factors associated with long-acting injectable cabotegravir-rilpivirine initiation in an urban academic HIV clinic
城市学术型HIV诊所中长效注射用卡博特韦-利匹韦林启动的资格及关联因素
Geoffroy Liegeon and others
Journal of Antimicrobial Chemotherapy, Volume 80, Issue 11, November 2025, Pages 3092–3100,
26
Evaluation of HIV-1 DNA resistance evolution in highly treatment-experienced and multi-resistant individuals under suppressive antiretroviral therapy: a longitudinal study from the PRESTIGIO Registry
在接受抑制性抗逆转录病毒治疗的高度治疗经验丰富和多药耐药个体中，HIV-1 DNA耐药演变的评估：来自PRESTIGIO登记处的纵向研究
D Armenia and others
Journal of Antimicrobial Chemotherapy, Volume 80, Issue 11, November 2025, Pages 3101–3106,
27
Sequential antibiotic exposure restores antibiotic susceptibility
序贯抗生素暴露恢复抗生素敏感性
Farhan R Chowdhury and Brandon L Findlay
Journal of Antimicrobial Chemotherapy, Volume 80, Issue 11, November 2025, Pages 3107–3117,
28
Dermatological adverse effects of doxycycline as post-exposure prophylaxis for sexually transmitted infections among men who have sex with men: real-world findings from a multicentre study
在男男性行为者中，使用多西环素作为性传播感染暴露后预防的皮肤科不良反应：一项多中心研究的现实发现
Ling-Ya Chen and others
Journal of Antimicrobial Chemotherapy, Volume 80, Issue 11, November 2025, Pages 3118–3122,
29
Phenotype–genotype discordance in antimicrobial resistance profiles of Gram-negative uropathogens recovered from catheter-associated urinary tract infections in Egypt
埃及导管相关尿路感染中分离的革兰氏阴性尿路病原菌抗菌药物耐药性表型-基因型不一致性
Mohamed Eladawy and others
Journal of Antimicrobial Chemotherapy, Volume 80, Issue 11, November 2025, Pages 3123–3132,
30
How should APOBEC3-induced resistance mutations be considered in the management of antiretroviral therapy?
在抗逆转录病毒治疗管理中，应如何考虑APOBEC3诱导的耐药突变？
Marie Gilbert and others
Journal of Antimicrobial Chemotherapy, Volume 80, Issue 11, November 2025, Pages 3133–3138,
31
In vitro evaluation of olorofim and antifungal combinations against Aspergillus and Candida species
奥洛芬和抗真菌药物组合对曲霉菌和念珠菌属的体外评价
Corinne Pinder and others
Journal of Antimicrobial Chemotherapy, Volume 80, Issue 11, November 2025, Pages 3139–3149,
32
Antagonistic interaction between posaconazole and olorofim in a murine model of invasive pulmonary aspergillosis
在侵袭性肺曲霉病小鼠模型中，泊沙康唑与奥洛芬之间的拮抗作用
Christopher A Darlow and others
Journal of Antimicrobial Chemotherapy, Volume 80, Issue 11, November 2025, Pages 3150–3159,
33
High level of archived and circulating HIV-1 drug resistance mutations in adolescents with a detectable viremia in Cameroon
喀麦隆可检测到病毒载量的青少年中HIV-1药物耐药突变的存档和循环水平较高
Armando B D Djiyou and others
Journal of Antimicrobial Chemotherapy, Volume 80, Issue 11, November 2025, Pages 3160–3164,
RESEARCH LETTERS（研究快讯）
34
SCY-247, a novel second-generation triterpenoid antifungal, demonstrates high in vitro activity against genetically diverse Candida auris isolates, including FKS1 mutants
新型第二代三萜类抗真菌药物SCY-247对包括FKS1突变体在内的多种基因型耳道假丝酵母菌显示出高体外活性
Bram Spruijtenburg and others
Journal of Antimicrobial Chemotherapy, Volume 80, Issue 11, November 2025, Pages 3165–3166,
35
Drug–drug interactions between tirzepatide and antiretrovirals: time to reassess and reassure?
替西帕肽与抗逆转录病毒药物之间的药物-药物相互作用：是时候重新评估和安心了吗？
Andrea Poloni and others
Journal of Antimicrobial Chemotherapy, Volume 80, Issue 11, November 2025, Pages 3167–3168,
36
Does the use of topical azoles have an impact on antifungal resistance?
局部使用唑类药物对抗真菌耐药性有影响吗？
Jean-Yves Maillard
Journal of Antimicrobial Chemotherapy, Volume 80, Issue 11, November 2025, Pages 3168–3186,
37
Leakage of cabotegravir and rilpivirine in HIV patients receiving long-acting injectable antiretroviral therapy
接受长效注射用抗逆转录病毒治疗的HIV患者中卡博特韦和利匹韦林的泄漏情况
Samir Benkouiten and others
Journal of Antimicrobial Chemotherapy, Volume 80, Issue 11, November 2025, Pages 3187–3188,
CORRECTION（更正）
38
Correction to: Clinical and microbiological analysis of bloodstream infections by four cefiderocol-resistant and not previously exposed NDM-producing Klebsiella pneumoniae
更正：对四种产NDM且之前未接触过头孢地洛的耐药肺炎克雷伯菌引起的血流感染的临床和微生物学分析
Journal of Antimicrobial Chemotherapy, Volume 80, Issue 11, November 2025, Page 3189,
Journal of Antimicrobial Chemotherapy Volume 80, Issue 12抗菌化疗杂志 80卷 12期
https://academic.oup.com/jac/issue
VIEWPOINT（观点）
1
Rifampicin as monotherapy for infections caused by Staphylococcus aureus: considerations for not applying ‘breakpoints in brackets’
利福平单药治疗金黄色葡萄球菌感染：关于不应用“括号内折点”的考量
Sara E Boyd and others
Journal of Antimicrobial Chemotherapy, Volume 80, Issue 12, December 2025, Pages 3191–3193,
REVIEWS（综述）
2
The Achilles’ heel of the Trojan Horse? A systematic evaluation of cefiderocol susceptibility testing
特洛伊木马的致命弱点？头孢地尔药敏试验的系统评价
Deny Tsakri and others
Journal of Antimicrobial Chemotherapy, Volume 80, Issue 12, December 2025, Pages 3194–3207,
3
Antifungal treatment strategies and their impact on resistance development in clinical settings
抗真菌治疗策略及其对临床环境中耐药性发展的影响
Norman Van Rhijn and P Lewis White
Journal of Antimicrobial Chemotherapy, Volume 80, Issue 12, December 2025, Pages 3208–3226,
ORIGINAL RESEARCH（论著）
4
Decrease in colistin resistance among young bovine and pig productions in France: relationship with colistin usage and stewardship measures
法国年轻牛和猪生产中多粘菌素耐药性的下降：与多粘菌素使用及管理措施的关系
Claire Chauvin and others
Journal of Antimicrobial Chemotherapy, Volume 80, Issue 12, December 2025, Pages 3227–3235,
5
Time to anti-cancer treatment resumption after SARS-CoV-2 infection in patients with active haematological diseases undergoing combined antiviral treatments
接受联合抗病毒治疗的活动性血液系统疾病患者感染SARS-CoV-2后恢复抗癌治疗的时间
E Matteini and others
Journal of Antimicrobial Chemotherapy, Volume 80, Issue 12, December 2025, Pages 3236–3241,
6
From TRIO to one: simplification to bictegravir/emtricitabine/tenofovir alafenamide in highly treatment-experienced people living with MDR HIV
从三联疗法到单一疗法：在多重耐药HIV感染且治疗经验丰富的人群中简化使用比克替拉韦/恩曲他滨/丙酚替诺福韦
José L Casado and others
Journal of Antimicrobial Chemotherapy, Volume 80, Issue 12, December 2025, Pages 3242–3247,
7
Effects of commonly used antibiotics on children’s developing gut microbiomes and resistomes in peri-urban Lima, Peru
秘鲁利马市郊常用抗生素对儿童发育中的肠道微生物组和耐药组的影响
Neha Sehgal and others
Journal of Antimicrobial Chemotherapy, Volume 80, Issue 12, December 2025, Pages 3248–3256,
8
Frailty Index Laboratory (FI-Lab) as predictor of poor outcomes for intra-hospital multidrug-resistant Klebsiella pneumoniae bloodstream infections: a single-centre retrospective cohort study
衰弱指数实验室（FI-Lab）作为预测院内多重耐药肺炎克雷伯菌血流感染不良预后的指标：一项单中心回顾性队列研究
Carmen Pellegrino and others
Journal of Antimicrobial Chemotherapy, Volume 80, Issue 12, December 2025, Pages 3257–3264,
9
Mechanisms of resistance to ceftazidime/avibactam in mutants derived in vitro from Klebsiella pneumoniae producing OXA-48-like enzymes
体外衍生的产OXA-48样酶肺炎克雷伯菌突变体对头孢他啶/阿维巴坦的耐药机制
T Blanco-Martín and others
Journal of Antimicrobial Chemotherapy, Volume 80, Issue 12, December 2025, Pages 3265–3272,
10
Comparative evaluation of disc diffusion and broth microdilution methods for aztreonam/avibactam susceptibility testing in Enterobacterales
肠杆菌目中氨曲南/阿维巴坦药敏试验的纸片扩散法和肉汤微量稀释法的比较评价
Ioannis Baltas and others
Journal of Antimicrobial Chemotherapy, Volume 80, Issue 12, December 2025, Pages 3273–3277,
11
Efficacy of topical hydrophilic gel of paromomycin combined with systemic or locally administered leishmanicidal drugs for treatment of experimental leishmaniasis caused by Leishmania (Viannia) braziliensis
硫酸巴龙霉素亲水性凝胶局部用药联合全身或局部使用杀利什曼原虫药物治疗巴西利什曼原虫（Viannia亚属）引起的实验性利什曼病的疗效
Líndicy Leidicy Alves and others
Journal of Antimicrobial Chemotherapy, Volume 80, Issue 12, December 2025, Pages 3278–3287,
12
Population pharmacokinetics and dosing optimization of cefoselis in paediatric patients with haematological malignancies
血液系统恶性肿瘤患儿中头孢噻利的群体药代动力学及剂量优化
Jing-Rui Liu and others
Journal of Antimicrobial Chemotherapy, Volume 80, Issue 12, December 2025, Pages 3288–3296,
13
Therapeutic challenges in treating ESBL- and/or AmpC-producing non-carbapenemase-producing Enterobacterales: an in vitro evaluation of novel β-lactam/β-lactamase inhibitor combinations and cefiderocol
治疗产超广谱β-内酰胺酶（ESBL）和/或AmpC酶且不产碳青霉烯酶的肠杆菌目细菌的挑战：新型β-内酰胺/β-内酰胺酶抑制剂组合和头孢地尔的体外评价
Inès Rezzoug and others
Journal of Antimicrobial Chemotherapy, Volume 80, Issue 12, December 2025, Pages 3297–3305,
14
Post-exposure prophylaxis with doxycycline (DoxyPEP) to prevent STIs in a real-world setting: the PRIDOX study
使用多西环素进行暴露后预防（DoxyPEP）以在现实环境中预防性传播感染：PRIDOX研究
R Palacios and others
Journal of Antimicrobial Chemotherapy, Volume 80, Issue 12, December 2025, Pages 3306–3310,
15
Risk–benefit balance of blood cultures among patients with stage IV cancer in unplanned admission: a nationwide propensity score–weighted study in Japan
日本全国范围内倾向评分加权研究：IV期癌症患者非计划入院时血培养的风险-获益平衡
Yuki Hashimoto and others
Journal of Antimicrobial Chemotherapy, Volume 80, Issue 12, December 2025, Pages 3311–3319,
16
A drug-repurposing screen of FDA- and EMA-approved drugs identifies two NF-κB inhibitors active against eumycetoma
对美国食品药品监督管理局（FDA）和欧洲药品管理局（EMA）批准的药物进行药物再利用筛选，发现两种对真性着色真菌病有活性的NF-κB抑制剂
Jingyi Ma and others
Journal of Antimicrobial Chemotherapy, Volume 80, Issue 12, December 2025, Pages 3320–3328,
17
Temocillin versus other intravenous beta-lactams for urinary tract infections caused by third-generation cephalosporin-resistant Enterobacterales: a multicentre retrospective matched cohort study
替莫西林与其他静脉注射β-内酰胺类药物治疗第三代头孢菌素耐药肠杆菌目引起的尿路感染：一项多中心回顾性匹配队列研究
Jeanne Iachkine and others
Journal of Antimicrobial Chemotherapy, Volume 80, Issue 12, December 2025, Pages 3329–3334,
18
Treatment preferences by infectious diseases clinicians for carbapenem-resistant Enterobacterales infections
感染科医生对碳青霉烯耐药肠杆菌目感染的治疗偏好
Samuel E Cincotta and others
Journal of Antimicrobial Chemotherapy, Volume 80, Issue 12, December 2025, Pages 3335–3339,
19
The aphA1 kanamycin and neomycin resistance gene originated in Klebsiella michiganensis
aphA1卡那霉素和新霉素耐药基因起源于密歇根克雷伯菌
Robert A Moran and Ruth M Hall
Journal of Antimicrobial Chemotherapy, Volume 80, Issue 12, December 2025, Pages 3340–3344,
20
Global susceptibility profiles and potential resistance mechanisms of ceftazidime–avibactam-resistant, non-carbapenemase-producing carbapenem-resistant Enterobacterales: 2020–23 data from the Antimicrobial Testing Leadership and Surveillance
头孢他啶-阿维巴坦耐药且不产碳青霉烯酶的碳青霉烯耐药肠杆菌目的全球易感性特征和潜在耐药机制：2020-2023年来自抗菌药物测试领导与监测的数据
Chih-Cheng Lai and others
Journal of Antimicrobial Chemotherapy, Volume 80, Issue 12, December 2025, Pages 3345–3351,
21
Comparative in vitro activity of ceftazidime-avibactam plus aztreonam and the fixed combination aztreonam/avibactam against multidrug-resistant Pseudomonas aeruginosa
头孢他啶-阿维巴坦联合氨曲南与固定组合氨曲南/阿维巴坦对多重耐药铜绿假单胞菌的体外活性比较
Sophie E Müller and others
Journal of Antimicrobial Chemotherapy, Volume 80, Issue 12, December 2025, Pages 3352–3356,
22
Dual β-lactam synergy in Enterococcus faecalis and its relationship with penicillin-ceftriaxone infective endocarditis treatment outcomes
粪肠球菌中双重β-内酰胺协同作用及其与青霉素-头孢曲松感染性心内膜炎治疗结果的关系
April Gregson and others
Journal of Antimicrobial Chemotherapy, Volume 80, Issue 12, December 2025, Pages 3357–3366,
23
The long walk to a short half-life: the discovery of augmented renal clearance and its impact on antibiotic dosing
走向短半衰期的漫长之路：发现肾增强清除及其对抗菌药物剂量调整的影响
Jeffrey Lipman and Russell E Lewis
Journal of Antimicrobial Chemotherapy, Volume 80, Issue 12, December 2025, Pages 3367–3374,
24
Aztreonam-amoxicillin/clavulanate combination therapy against blaNDM-producing Enterobacterales infections
氨曲南-阿莫西林/克拉维酸联合治疗产blaNDM肠杆菌目感染
Efrat Orenbuch-Harroch and others
Journal of Antimicrobial Chemotherapy, Volume 80, Issue 12, December 2025, Pages 3375–3380,
25
Evaluation of sodium zirconium cyclosilicate usage for hyperkalaemia secondary to sulfamethoxazole/trimethoprim therapy
评估锆酸钠环硅酸盐用于磺胺甲恶唑/甲氧苄啶治疗继发的高钾血症
Dixie Pyles and others
Journal of Antimicrobial Chemotherapy, Volume 80, Issue 12, December 2025, Pages 3381–3385,
26
Thrice-weekly post-haemodialysis ceftazidime can achieve adequate pre-dialysis concentrations and clinical cure in patients with melioidosis
每周三次血液透析后使用头孢他啶可在类鼻疽患者中达到足够的透析前浓度并实现临床治愈
Simon Smith and others
Journal of Antimicrobial Chemotherapy, Volume 80, Issue 12, December 2025, Pages 3386–3390,
27
In vitro and clinical data demonstrate negligible risk of drug–drug interactions with opelconazole, a novel inhaled antifungal agent
体外和临床数据表明，新型吸入抗真菌药物奥培康唑的药物-药物相互作用风险可忽略不计
Lindsey M R Cass and others
Journal of Antimicrobial Chemotherapy, Volume 80, Issue 12, December 2025, Pages 3391–3400,
28
Antifungal prophylaxis in patients with FMS-like tyrosine kinase 3-internal tandem duplication (FLT3-ITD)–positive acute myeloid leukaemia receiving sorafenib during initial induction and consolidation treatment in ALLG AMLM16 trial
在ALLG AMLM16试验中，FLT3-ITD阳性急性髓系白血病患者在初始诱导和巩固治疗期间接受索拉非尼治疗时的抗真菌预防
Chin Fen Neoh and others
Journal of Antimicrobial Chemotherapy, Volume 80, Issue 12, December 2025, Pages 3401–3406,
29
The synergistic activity of tigecycline-based combinations against multidrug-resistant Acinetobacter baumannii-caused bloodstream infections
基于替加环素的联合用药对多重耐药鲍曼不动杆菌引起的血流感染的协同活性
Huan Zhang and others
Journal of Antimicrobial Chemotherapy, Volume 80, Issue 12, December 2025, Pages 3407–3418,
30
Piperacillin dosing in pediatric patients and augmented renal clearance: are current guidelines sufficient to achieve therapeutic concentration coverage?
儿科患者中哌拉西林的剂量调整与肾增强清除：现行指南是否足以达到治疗浓度覆盖？
Anne Ravix and others
Journal of Antimicrobial Chemotherapy, Volume 80, Issue 12, December 2025, Pages 3419–3430,
31
Efficacy of human-simulated aztreonam-avibactam against Stenotrophomonas maltophilia in the neutropenic murine thigh infection model
在中性粒细胞减少的小鼠大腿感染模型中评估人模拟氨曲南-阿维巴坦对嗜麦芽窄食单胞菌的疗效
Yakun Fu and others
Journal of Antimicrobial Chemotherapy, Volume 80, Issue 12, December 2025, Pages 3431–3437,
32
A prospective assessment of the efficacy and durability of long-acting cabotegravir and rilpivirine in individuals with HIV in Spain (RELATIVITY study)
西班牙HIV感染者长期使用卡博特韦和利匹韦林的有效性和持久性的前瞻性评估（RELATIVITY研究）
Luis Buzón-Martín and others
Journal of Antimicrobial Chemotherapy, Volume 80, Issue 12, December 2025, Pages 3438–3451,
33
Antagonistic in vitro interaction between olorofim and voriconazole against Aspergillus fumigatus
奥洛罗芬和伏立康唑对烟曲霉的体外拮抗作用
Illan Laloum and others
Journal of Antimicrobial Chemotherapy, Volume 80, Issue 12, December 2025, Pages 3452–3461,
RESEARCH LETTERS（研究快讯）
34
Concomitant IV vancomycin causing delayed high-dose methotrexate clearance and acute kidney injury
静脉注射万古霉素联用导致大剂量甲氨蝶呤清除延迟和急性肾损伤
Thao Dao and others
Journal of Antimicrobial Chemotherapy, Volume 80, Issue 12, December 2025, Pages 3462–3464,
35
Overestimation of piperacillin/tazobactam resistance in Escherichia coli by disc diffusion and gradient strip methods
纸片扩散法和梯度条法高估大肠埃希菌对哌拉西林/他唑巴坦的耐药性
Stefano Mancini and others
Journal of Antimicrobial Chemotherapy, Volume 80, Issue 12, December 2025, Pages 3464–3467,
36
Mind the gap: missed re-initiation and monitoring in statin–antimicrobial co-prescriptions
注意差距：他汀类药物与抗菌药物联合处方中的漏重新起始和监测
Melwin Kyle Solis and others
Journal of Antimicrobial Chemotherapy, Volume 80, Issue 12, December 2025, Pages 3467–3468,
37
Pharmacokinetics of aztreonam/avibactam in a critically ill patient with a class B metallo-β-lactamase producing Enterobacteriaceae and receiving continuous renal replacement therapy
一名接受连续肾脏替代治疗且感染产B类金属β-内酰胺酶肠杆菌科细菌的重症患者中氨曲南/阿维巴坦的药代动力学
Daniel Fresán and others
Journal of Antimicrobial Chemotherapy, Volume 80, Issue 12, December 2025, Pages 3469–3471,
CORRECTION（更正）
38
Correction to: Systematic reviews and the Journal of Antimicrobial Chemotherapy; past, present and future. A systematic reappraisal
更正：系统评价与《抗菌药物化疗杂志》：过去、现在和未来。一项系统再评价
Journal of Antimicrobial Chemotherapy, Volume 80, Issue 12, December 2025, Pages 3472–3473,
2025-12-02
2024年5月1日起，行政相对人可登录国家药品监督管理局政务服务门户——我的办件中查看电子文书，按照相关提示自行打印。序号受理号药品名称申请人签发日期1CXSS2400137重组质粒-肝细胞生长因子注射液武汉光谷人福生物医药有限公司2025年12月01日2CYHB2450528阿奇霉素颗粒海口奇力制药股份有限公司2025年12月01日3JYSB2500260甘精胰岛素利司那肽注射液（Ⅱ）赛诺菲（中国）投资有限公司2025年12月01日
2025-12-02
本 期 导 读
企业动态
近日，齐鲁制药注射用拉氧头孢钠获得国家药品监督管理局批准上市，齐鲁抗生素家族又添一位新成员，这也是公司上市的第79个抗感染药物。齐鲁制药于2022年启动注射用拉氧头孢钠的研究开发……
原文《齐鲁制药抗感染家族添新员“注射用拉氧头孢钠”获批上市》
印度市场
印度原料药（API）企业目前正面临重大挑战，“政府必须采取保护措施，例如设定最低进口价格（MIP）或征收反倾销税，以保护这些具有战略意义的投资。若无此类干预，国内制造商将面临关闭风险，这将损害‘生产关联激励计划’（PLI）的核心目标。这一问题应被视为关乎国家供应安全的战略事项……
原文《印度原料药企业呼吁实施反倾销税和最低进口价格等保护主义政策》
市场分析
根据健康网的最新数据，中国皮肤病用药市场规模在2024年已突破----亿元，过去五年复合增长率高达18.61%。当系统性治疗药物历史性反超传统外用制剂，上游原料药领域正迎来一场深刻的战略重构。市场变革：下游需求驱动上游洗牌……
原文《皮肤类原料药赛道抉择：传统激素稳中求变，创新靶点蓄势待发》
本 期 目 录
企业动态
生物催化系列 — 醇氧化酶
山东某公司投资改建新增瓦伦烯、佛术烯、红没药烯、檀香醇、红没药醇等项目
浙江某公司投资1.97亿元新建天然肠衣及肝素钠粗品项目
山东某公司扩建新增原料药丁苯酞和乌帕替尼项目、替戈拉生产能不变
山东某公司投资4.29亿元原料药改扩建项目(美罗培南、头孢呋辛钠、头孢美唑钠等)
山东某公司原料药改建项目一期新增比阿培南、利伐沙班、艾司奥美拉唑镁等
江西某公司技改生产醋酸可的松和氢化可的松中间体项目
江西某公司投资5亿元扩建精细化学品项目一期4-溴甲基喹啉酮、3-氯咔唑等
焦点福瑞达“注射级玻璃酸钠”原料药获CDE“I”状态登记号
维生素健康养殖产学研合作基地(日照)正式揭牌，攻关水产养殖动物维生素营养健康
河北国龙制药“维生素A棕榈酸酯”原料药获批
江西富祥药业“他唑巴坦”原料药获巴西国家卫生监督局GMP认证
联邦制药“注射用头孢哌酮钠舒巴坦钠”通过一致性评价
瑞邦生物“烟酰胺”获评安徽省未来产业标志性产品
安徽某公司“2,3,6-三甲基苯酚”推动维生素E产业链降本增效
宁夏某公司左旋肉碱系列技改项目获批，建成后成为最大左旋肉碱生产基地
25-羟基维生素D3企业携手中国农大王爱国教授，共筑维生素营养新篇章
河北某公司扩建天然营养健康产品生产项目竣工及原材料消耗情况表
内蒙古某公司投资建纳米晶项目(姜黄素纳米晶、辅酶纳米晶、槲皮素纳米晶)
11月21日云南爱尔康雨生红球藻提取天然虾青素项目二期开通建设
江西某公司新建25-羟基维生素D3项目竣工环保验收
甘肃某公司利福霉素S钠盐投产后，谋划二期项目建设
惠欣药业合成生物学绿色智造产业化建设项目一期完成，2026年4月试产
安徽华恒生物入选国家首批生物制造中试能力建设平台
拉曼动物营养全球总裁Mathieu CASTEX拜访中国区经销商及客户
拉曼集团动物营养总裁参观25-羟基维生素D3企业洽谈合作
市场总局：辅酶Q10和褪黑素增补剂型和辅料按程序推进
山东某公司原料药维生素K1成功转“A”
广东某公司投资近亿元扩建食品营养强化剂叶酸项目及全厂产品方案
共同药业：通过创新一站式解决方案，实现与客户共赢
陕西某公司合成生物学高附加值产品研发项目竣工验收(红没药醇、法尼醇等)
云南白药与爱尔发强强联手，虾青素天麻精片焕新上市
维卓（嘉兴）营养品有限公司荣膺市级绿色工厂称号
山东某公司投资0.7亿元酵母生产线提质项目，增加酵母发酵、抽提物产能
维生素D3企业：花园生物备战2026年“小巨人”企业复审
安徽某公司扩建麦角硫因、N-乙酰氨基葡萄糖项目竣工验收，取消γ-氨基丁酸生产
湖南某公司改扩建12种原料药及实验室项目，有哪些产品？
普洛药业子公司“头孢地尼胶囊”获得药品注册证书
东北制药产供销高效联动，2025年四季度开局稳中有进
江苏某公司技改多肽合成保护剂（N-羟基丁二酰亚胺）项目
齐鲁制药抗感染家族添新员“注射用拉氧头孢钠”获批上市
浩天药业新产品“手性肌醇、鲨肌醇、维生素PQQ”顺利通过多项体系认证
安徽某公司投资1.61亿元新建复方抗生素及独家原料药项目
华北制药华民公司“注射用头孢噻肟钠”获评省级“制造业单项冠军企业”
国内某公司在高端吸入粉雾剂领域实现突破，沙美特罗替卡松将提交上市申请
制剂出海传捷报：津药药业“注射用甲泼尼龙琥珀酸钠”获巴拿马注册证书
辽宁某公司氨基丁酸技术改造降低污染及生产成本，产能多少吨？
农业、食品与营养巨头ADM：利用‘价值链’来连接农民与消费者
海正药业子公司拟与华东院合作生物法合成肝素项目
湖南文理学院创新合成生物学人才引培模式，支撑赋能地方新质生产力发展
浙江省“十链百场万企”聚焦合成生物产业链对接专场在绍兴举行
开元制药（安徽）有限公司磷霉素产品走差异化路径
盐酸林可霉素企业：新宇药业斥资近2亿元打造数字化绿色节能生产线
“福建药谷”的崛起形成两条特色产业链(紫杉醇、七氟烷)
科技特派团：供需对接为甾体激素企业突破产业“卡脖子”技术壁垒
仙居2家甾体激素企业入选2025年浙江省先进级智能工厂名单
仙琚制药赴乌兹别克斯坦开展“一带一路”经贸合作探索之行
山东汇海医药化工“头孢类中间体三嗪环的绿色合成技术”荣获优胜奖
襄城“妙招”破解湖北凌晟药业融资困局
天方药业奋战2025年四季度确保全年红，原料药锁定明年1.2亿元海外订单
广东金城金素制药：逆袭抗生素赛道的“新势力”
金城医药子公司“谷胱甘肽”原料药获得欧洲CEP证书
中科院天津工生所通过木糖-乙酸共利用显著提升β-胡萝卜素生物合成效率
欧盟批准D-泛酸钙和D-泛醇作为所有动物的饲料添加剂
山东原力泰掘金抗衰市场，打造明星原料“维生素PQQ、麦角硫因、神经酸”等
“创新、人和、竞成”新和成以科技创新铸就实业根基，展望“十五五”
启臻研究院破解合成生物成果转化难题，他克莫司、达托霉素等中试放大
广西某公司改扩建头孢类中间体项目(头孢曲松钠、头孢噻肟酸、7-ACF)
广西某公司扩建医药中间体项目(（二氯磷酸苯酯)
河北某公司技改扩建盐酸二氧丙嗪、奥昔布宁、愈创木酚磺酸钾等项目
湖北某公司投资1.5亿元新建医药中间体项目(N-乙基胡椒胺、1-氯-1，1-二氟甲氧基-4-硝基苯)
山东某公司磷酸奥司他韦干混悬剂生产线改造项目，原料药年消耗多少吨？
山东某公司新建粉液双室袋项目，消耗头孢曲松、头孢他啶、阿维巴坦钠多少吨？
江苏某公司投资0.25亿元建设新药研发中试平台及新药研发改扩建项目
新疆某公司发酵法生产L-高丝氨酸关键技术及产业化项目获奖
AEO助力“新和成”开启亚太经合组织(APEC)市场新航道，出口增加多少？
新疆沂利泓生物新材料科技有限公司出口许可新增“L-色氨酸”
新疆沂利泓生物新材料科技有限公司2025年预计产量10-12亿元
吉林某公司利用呋喃铵盐等生产线新增AE-活性酯、2-氮杂双环(2.2.1)庚-5-烯-3-酮项目
新疆某公司对现有亮氨酸、维生素B12等生产线技改新增年L-高丝氨酸、异维生素C钠或泛酸钙项目
山东某公司年产4万吨大豆分离蛋白提质增产项目竣工环保验收
山东某公司新建生物抗氧化产品研发及精深加工项目(大蒜素、功能性食品及饮料)
吉林某公司投资扩建多肽研发中试项目
11月13日国家药监局领导在浙江调研原料药管理工作
新田生物科技(新疆)有限公司高端胶原蛋白肠衣技术填补国内空白
甘肃某公司投资扩建化妆品活性物(维生素衍生物等)项目，视黄醇、维生素A醛、维生素C四异棕榈酸酯等
内蒙古某公司新建年产30万吨苏氨酸及其配套项目
新疆某公司氨基酸生产线柔性化改扩建项目，新增叶酸、L-组氨酸、瑞鲍迪苷、D-苯丙氨酸、氨基葡萄糖等产品
巴斯夫扩建露他维A项目，维生素A油及维生素E油需求多少吨？
浙江某公司投资新建类胡萝卜素、维生素制品及配套项目竣工环保验收
山东某公司推进肌醇和甘露糖醇类药物向绿色生物制造转型升级
山东奥博生物：以科技赋能生物制造,凭创新叩响全球市场
赛托生物子公司“糠酸莫米松”获得化学原料药上市申请批准
江苏某公司“左炔诺孕酮”原料药通过世卫组织预认证现场检查
华北制药华民公司头孢托仑匹酯原料药获批上市
运动营养品牌“迈胜”完成近亿元A轮融资
诺特兰德推出「DHA磷脂酰丝氨酸叶黄素酯」
上海麦角硫因生物科技集团Dr.Ergo?以99.99%超高纯度引领抗氧化原料创新
双雁集团子公司上海邦林生物荣获国家级专精特新“小巨人”企业认定
2025进博会：京东健康联合善存启动《大脑维生素白皮书》编制
保健品企业：山东斯伯特全力迎战“双十一”冲刺全年销售目标
山东某公司改建新增海藻糖、L-组氨酸和L-苯丙氨酸生产项目
山东某公司投资利用高端赤鲜糖醇项目改建高品质氨基酸改建项目竣工验收生产(70%赖氨酸)
山东某公司改建赤藓糖醇、赖氨酸生产线新增L-精氨酸柔性生产项目竣工验收投产
山东某公司投资改建赤藓糖醇生产线柔性生产缬氨酸、亮氨酸(异亮氨酸)、赤藓糖醇项目竣工验收
江西某公司生物发酵法生产阿尼芬净、卡泊芬净、多拉菌素、安丝菌素、硫酸多粘菌素B项目竣工验收，产能多少吨？
浙江某公司投资新建合成生物学高效绿色制造项目竣工验收(根皮素、塔格糖和紫杉醇)
山东某公司投资新建α-硫辛酸、右旋硫辛酸钠、右旋硫辛酸中间体、右旋硫辛酸氨基丁三醇项目竣工验收
湖北某公司投资改建医药中间体生产线项目(2-溴丙酸乙酯、2-溴丁酸乙酯、2-硝基-3,5-二溴苯甲醛等)
红杉中国21亿抄底拜耳王牌抗生素Avelox(莫西沙星)
山东某公司投资0.6亿元技改生产头孢泊肟母核(7-AMCA)和头孢泊肟酯项目
山东某公司维生素D3结晶提纯猪用饲料添加剂产品项目，外购维生素D3光化油
广东某公司投资饲料用类胡萝卜素复配生产工艺改造项目
安徽某公司投资扩建膳食纤维(聚葡萄糖)项目竣工环保验收
内蒙古某公司投资取消土霉素系列产品改建凉味剂WS-5项目
河南某公司扩建利福霉素S酸、利福布汀PQ、利福平、利福昔明等项目竣工试产
浙江医药昌海生物分公司投资异戊烯醛、三甲基苯醌技改提升项目
浙江某公司投资维生素E前体衍生产品等技改提升项目(异丙叉丙酮、四氢芳樟醇、天然维生素E等)
海文生物携化妆品级烟酰胺重磅亮相2025亚洲化妆品原料泰国展
烟酰胺企业：瑞邦生物让“边角料”闯进高端市场
万华化学“一种维生素A异构化的方法”获得发明专利授权
金达威“一种6-氯-6-氧代己酸乙酯的连续制备装置及方法”获发明专利
赛托生物子公司“甲泼尼龙”获得化学原料药上市批准
华北制药河北华民药业“头孢托仑匹酯”获得化学原料药上市批准
富祥药业再次顺利通过美国FDA现场检查
山东某公司投资0.96亿元新建高端食品医药氨基酸项目(富马酸、L-天门冬氨酸及5个医药级氨基酸)
山东某公司投资1.48亿元扩建食品级氨基酸项目(新增7个产品、L-酪氨酸增加产能)
浩天药业“鲨肌醇”从海洋珍稀成分到绿色生物制造的突破
湖北某公司投资功能性健康食品生产线技术改造和智能化升级项目
江苏某公司投资扩建异麦芽酮糖及肌醇生产项目获批复，产能多少吨？
安徽某公司氨基酸系列食品添加剂项目，调整工艺产能不变(L-瓜氨酸、L-精氨酸-α-酮戊二酸、硫酸胍基丁胺、赖氨酸)
湖北某公司扩建多不饱和脂肪酸系列ARA油脂和DHA油脂项目
浙江某公司投资0.6亿元维生素E、鱼油等软胶囊技改项目竣工验收
浙江横店普洛进出口有限公司获海关贸易型AEO高级认证
福建某公司投资扩建新增叶酸生产项目，产能设计多少吨？
湖北某公司投资7.85亿元新建维生素B6、硫辛酸及化学合成原料药项目获批复，产能多少吨？
福安药业子公司庆余堂获菲律宾GMP符合性证书
康达制药：头孢类原料药技术创新引领“智绿”转型
金河生物：虾青素产品落地，加快合成生物学在产业应用和布局
金河生物“红法夫酵母”获得饲料添加剂产品批准文号
音芙医药2025美国SSG展落幕，焦点聚集于NAD+抗衰领域
维生素D3企业：花园生物成功入选2025年度浙江省管理现代化企业名单
到期换证：浙江某公司获维生素K3饲料添加剂生产许可证
湖北某公司获β-阿朴-8-胡萝卜素酸乙酯(阿卜酯)饲料添加剂生产许可证
湖北某公司获β-胡萝卜素、DHA饲料添加剂生产许可证
河北某公司获虾青素、斑蝥黄饲料添加剂生产许可证
到期换证：浙江某公司获D-泛酸钙、D-泛醇饲料添加剂生产许可证
金城医药“谷胱甘肽和头孢克肟侧链酸活性酯”获批国家级制造业单项冠军企业
韩国CJ集团与色素公司Michroma布局生物合成色素
和泽医药与梯瓦达成舒美特(阿奇霉素)商业合作，携手推进在中国商业化进程
盛德百泰亮相2025美国SSG展：重点推广植物源维生素D3及维生素K2产品
津药药业亮相2025年CPHI欧洲展，收获新增订单及长期合作意向
维生素C企业：江山制药美国SSG展圆满收官，重点推广新产品
巴斯夫投资新建薄荷醇和芳樟醇下游装置将在2026年起投产
圣诺生物多肽原料药基地开工建设，剑指全球GLP-1市场缺口
盐酸二甲双胍原料药“卡脖子”技术难题得到解决，订单排到2026年1季度
海佑福瑞达“格列齐特”原料药获得欧洲CEP证书
江西天新药业股份有限公司顺利通过韩国MFDS认证！
维生素D3产业链企业：江西某公司已投产上市销售
新和成回复：维生素A和维生素E饲料级现有产能多少吨？
石四药集团“维生素B6注射液”通过仿制药质量和疗效一致性评价
安徽某公司技改实现鱼油与羊毛脂、胆固醇及胆汁酸自动化生产，降低生产成本
黑龙江某公司投资改建L-丙氨酸、L-异亮氨酸、维生素C磷酸酯钠、α-熊果苷等项目
奈雪“小绿瓶”行业首用D-阿洛酮糖，获低GI认证
微元合成“一步发酵法生物合成工艺”阿洛酮糖快速走向市场
河南省市场监管局为新食品原料(D-阿洛酮糖)定制特定生产许可审查方案
福宽生物与中粮集团达成合作，强强联手开启“减糖革命”(阿洛酮糖)
山东福宽生物工程有限公司：玉米精深加工的国企标杆与创新领航者
安徽某公司投资1.28亿元三氯蔗糖技术改造降低成本，总产能达到多少吨？
总投资10亿元辽宁某公司新建年产6万吨D-阿洛酮糖项目开工建设
罗盖特启动淀粉及多元糖醇研发中心
山东奔月：甜菊糖苷RM高效生物合成产线正式竣工
莱茵生物：前三季度实现营业收入12.72亿元，同比增长8.73%
河南益恒源生物科技有限公司推出塔格糖
上海麦角硫因集团推出高纯度麦角硫因与雌马酚
行情走势
维生素E厂家停报中，热度快速降温
叶酸中间体缺货，价格继续走高
2025年1-10月中国出口磺胺类原料药约5.98亿美元
2025年10月中国出口磺胺类原料药约5133万美元
2025年1-10月中国出口提取物类产品约5.6美元
2025年10月中国出口提取物类产品约5525万美元
2025年1-10月中国出口抗生素原料药约36亿美元
2025年10月中国出口抗生素类原料药约3.2亿美元
2025年1-10月中国出口激素类原料药约14.5亿美元
2025年1-10月中国出口激素类原料药约14.5亿美元
2025年10月中国出口激素类原料药约1.4亿美元
2025年1-10月中国出口维生素类产品约31.5亿美元
2025年10月中国出口维生素类产品约2.5亿美元
2025年1-10月中国进口药品制剂约188.7亿美元
2025年10月中国进口药品制剂约18.7亿美元
2025年1-10月中国出口氨基酸类产品约48.4亿美元
2025年10月中国出口氨基酸类产品约4亿美元
2025年1-10月中国出口药品制剂约67.5亿美元
2025年10月中国出口药品制剂约9.35亿美元，大增89%
国内原料药行情每周要闻回顾（2025年第47周）
国内原料药行情每周要闻回顾（2025年第46周）
国内原料药行情每周要闻回顾（2025年第45周）
国内原料药行情每周要闻回顾（2025年第44周）
欧洲建设维生素D3生产基地，将减少对进口的依赖
维生素B1的稳定性困境与破解之道
印度原料药企业呼吁实施反倾销税和最低进口价格等保护主义政策
2025年10月份印度制药产品出口量下降了 5.15%
印度药品监管局（CDSCO）要求采购机构将印度药品许可证作为技术要求加以规定
印度制药市场近五年年复合年增长率超过10%
尼日利亚医药市场分析
皮肤类原料药赛道抉择：传统激素稳中求变，创新靶点蓄势待发
兽药市场
国邦医药携手中牧股份，共筑动保医药供应链新生态
内蒙古某公司六期新建兽药级高效金霉素及迁建土霉素项目竣工环保验收
广西某公司新建兽药原料“右旋糖酐铁”项目竣工环保验收
山东某公司投资1.14亿元扩建兽用酒石酸泰乐菌素、磷酸泰乐菌素原料药项目，有多大产能？
山东某公司投资3.2亿元新建兽用头孢原料药项目，有哪些产品？
某公司与高校开展产学研，将兽药原料工艺优化降低生产成本
联邦制药(内蒙古)有限公司顺利通过氨苄西林兽药生产许可证及GMP验收
可克达拉金海生物氨基酸系列产品正式进入调试期
兰西哈三联制药二类新兽药“氟雷拉纳”原料药取得批准文号
2025年前三季度兽药原料“五小强”出口均超7000万美元
《医药原料市场信息月刊》
QQ咨询：2953555391
《医药原料市场信息月刊2025》订购登记表
刊物定价：月价：1000元/期。
年价：10000元/年，分12期按月提供。
详情请点“阅读原文”
版权归作者和东方比特-健康网共同所有
欢迎关注健康网产业微信，更多内容请访问www.healthoo.com
健康网独家推出《医药原料药市场信息月刊》，内容主要汇集当月原料药行业信息精华，其中包括行业动态、行情走势、市场点评和兽药信息四个部分。欢迎订购！
医药原料药市场信息月刊2025年11月刊
维生素市场信息月刊2025年11月
QQ：2953555391（原料药信息月刊）
电话：010-68012929-2106周经理
一致性评价上市批准引进/卖出
100 项与 阿奇霉素 相关的药物交易
登录后查看更多信息
研发状态
批准上市
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 生殖器感染 | 韩国 | 2024-06-28 | |
| 下呼吸道感染 | 韩国 | 2024-06-28 | |
| 中耳炎 | 韩国 | 2024-06-28 | |
| 皮肤结构和软组织感染 | 韩国 | 2024-06-28 | |
| 睑缘炎 | 日本 | 2019-06-18 | |
| 泪囊炎 | 日本 | 2019-06-18 | |
| 睑腺炎 | 日本 | 2019-06-18 | |
| 细菌性结膜炎 | 美国 | 2007-04-27 | |
| 急性细菌性鼻窦炎 | 美国 | 2005-06-10 | |
| 急性支气管炎 | 日本 | 2000-03-10 | |
| 喉炎 | 日本 | 2000-03-10 | |
| 肺脓肿 | 日本 | 2000-03-10 | |
| 淋巴结炎 | 日本 | 2000-03-10 | |
| 冠周炎 | 日本 | 2000-03-10 | |
| 牙周炎 | 日本 | 2000-03-10 | |
| 咽炎 | 日本 | 2000-03-10 | |
| 呼吸道感染 | 日本 | 2000-03-10 | |
| 鼻窦炎 | 日本 | 2000-03-10 | |
| 皮肤和皮肤结构感染 | 日本 | 2000-03-10 | |
| 扁桃体炎 | 日本 | 2000-03-10 |
未上市
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 炎症 | 临床3期 | 马里 | 2020-10-15 | |
| 疟疾 | 临床3期 | 马里 | 2020-10-15 | |
| 新型冠状病毒感染 | 临床3期 | 美国 | 2020-05-22 | |
| 寻常痤疮 | 临床3期 | 意大利 | 2007-10-01 | |
| 咽喉炎 | 临床3期 | 日本 | 2006-11-01 | |
| 慢性呼吸道疾病 | 临床3期 | 日本 | 2006-10-01 | |
| 哮喘 | 临床3期 | 美国 | 2006-01-01 | |
| 急性细菌性结膜炎 | 临床3期 | 美国 | 2004-07-01 | |
| 猩红热 | 临床3期 | 美国 | 2003-05-01 | |
| 猩红热 | 临床3期 | 加拿大 | 2003-05-01 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
| 研究 | 分期 | 人群特征 | 评价人数 | 分组 | 结果 | 评价 | 发布日期 |
|---|
临床3期 | - | 1,151 | Placebo | 簾淵積選醖遞製衊鏇醖(廠壓鏇積膚廠構餘繭憲) = Adverse events were rare, and the percentages of infants with adverse events were similar in the three groups. 憲醖窪衊鏇齋窪構選構 (遞淵糧齋鑰憲遞繭廠壓 ) 更多 | 不佳 | 2025-10-16 | |
临床3期 | - | 54 | Standard of care plus azithromycin | 鹹繭餘選糧獵願憲艱築(構膚憲齋鹹蓋齋蓋積遞) = 選襯鹽壓蓋壓鬱壓獵壓 鑰製範鬱齋艱壓膚廠範 (淵艱鑰築鏇選壓觸窪鹽, 45 ~ 118) 更多 | 不佳 | 2025-10-01 | |
Standard of care | 鹹繭餘選糧獵願憲艱築(構膚憲齋鹹蓋齋蓋積遞) = 鏇積蓋鹹獵獵齋製糧鹽 鑰製範鬱齋艱壓膚廠範 (淵艱鑰築鏇選壓觸窪鹽, 20 ~ 123) 更多 | ||||||
临床3期 | 60 | 構顧餘餘遞積夢獵廠構(齋鬱積築遞積積遞構顧) = 襯構蓋簾膚襯襯廠獵壓 獵襯築顧築廠繭淵醖繭 (顧鹽廠顧顧醖築糧襯選 ) 更多 | 不佳 | 2025-10-01 | |||
Placebo | 構顧餘餘遞積夢獵廠構(齋鬱積築遞積積遞構顧) = 範憲窪製顧壓艱鹹鑰鹽 獵襯築顧築廠繭淵醖繭 (顧鹽廠顧顧醖築糧襯選 ) 更多 | ||||||
临床3期 | 4,726 | 鹹範餘鏇範鬱鑰顧齋齋(鬱壓簾網製糧構網艱艱) = 遞衊壓鏇積鏇窪壓蓋網 築廠淵衊鏇構糧蓋憲觸 (壓積顧蓋糧願顧艱膚襯, 5.1 ~ 15.7) | 积极 | 2025-08-18 | |||
Placebo | 鹹範餘鏇範鬱鑰顧齋齋(鬱壓簾網製糧構網艱艱) = 鬱廠糧繭鹹廠願鏇糧壓 築廠淵衊鏇構糧蓋憲觸 (壓積顧蓋糧願顧艱膚襯, 4.0 ~ 12.6) | ||||||
临床4期 | 864,493 | Placebo+Azithromycin (Azithro 1-11) | 選餘製餘鬱願鬱遞鬱觸 = 鑰夢鏇淵艱鏇簾製糧廠 鹹鹽鏇壓築夢鏇鹹鏇鹽 (鬱構夢窪餘窪選廠鹹淵, 獵鬱遞淵餘廠鑰膚壓夢 ~ 顧選範憲廠鑰鏇網夢壓) 更多 | - | 2025-05-14 | ||
(Azithro 1-59) | 選餘製餘鬱願鬱遞鬱觸 = 齋齋遞鏇鏇窪繭憲壓憲 鹹鹽鏇壓築夢鏇鹹鏇鹽 (鬱構夢窪餘窪選廠鹹淵, 醖膚衊淵築鏇顧憲襯顧 ~ 鬱淵鹹繭觸顧廠積繭廠) 更多 | ||||||
临床4期 | 103 | Asthma Symptom Monitoring online tools (Enhanced Usual Care) | 憲衊鏇構獵網遞淵製衊(選製範淵積築遞壓鹽簾) = 積觸鹽製選鬱範窪齋鬱 齋選繭壓淵窪鑰夢獵衊 (壓顧艱範餘簾淵獵顧製, 3.82) 更多 | - | 2025-04-20 | ||
Inhaled Steroids (Rescue Inhaled Corticosteroids) | 憲衊鏇構獵網遞淵製衊(選製範淵積築遞壓鹽簾) = 廠網構壓窪選夢鬱構餘 齋選繭壓淵窪鑰夢獵衊 (壓顧艱範餘簾淵獵顧製, 3.72) 更多 | ||||||
临床3期 | 310 | (Amoxicillin) | 糧鏇餘蓋蓋膚簾淵蓋衊(夢顧網鹹蓋廠鹹廠範壓) = 窪憲範糧鏇獵遞遞廠衊 齋憲顧鹹顧憲糧鬱遞繭 (艱蓋廠醖膚醖糧鬱遞鹹, 17.11) 更多 | - | 2025-02-25 | ||
(Azithromycin) | 糧鏇餘蓋蓋膚簾淵蓋衊(夢顧網鹹蓋廠鹹廠範壓) = 簾製獵糧繭鹽網醖製製 齋憲顧鹹顧憲糧鬱遞繭 (艱蓋廠醖膚醖糧鬱遞鹹, 18.82) 更多 | ||||||
临床4期 | - | 77,664 | (Biannual Mass Oral Azithromycin) | 鹽願壓鹹衊範願衊鬱齋 = 淵淵窪餘製襯製鏇鹹憲 積蓋鹹鑰獵淵鏇憲糧鬱 (窪顧鹹襯鹹壓鹽襯衊選, 餘糧衊襯鬱鹽範積齋觸 ~ 鑰齋糧鏇製鏇遞窪醖糧) 更多 | - | 2025-02-24 | |
Placebos+Azithromycin (Biannual Mass Oral Placebo) | 鹽願壓鹹衊範願衊鬱齋 = 範範壓獵糧鹹鹹齋構築 積蓋鹹鑰獵淵鏇憲糧鬱 (窪顧鹹襯鹹壓鹽襯衊選, 製顧餘鬱鬱範壓願襯鏇 ~ 獵顧醖鏇襯襯壓齋醖鬱) 更多 | ||||||
临床2期 | 10 | 簾醖築選積衊蓋廠窪選 = 廠鏇鹽鹹糧廠鏇繭積齋 廠壓繭餘壓鑰鹽窪醖襯 (範繭獵夢範糧壓繭鑰獵, 選糧醖獵構壓築餘簾願 ~ 築襯鹽齋艱選選選選衊) 更多 | - | 2025-01-22 | |||
临床3期 | - | Adjunctive Azithromycin Prophylaxis | 簾鬱鏇鹽醖觸顧製膚糧(憲壓鏇獵夢鬱廠艱鏇窪): OR = 1.06 (95% CI, 0.77 ~ 1.46), P-Value = 0.42 | 积极 | 2024-12-01 | ||
Placebo |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
生物医药百科问答
全新生物医药AI Agent 覆盖科研全链路，让突破性发现快人一步
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用